<PAGE>
As filed with the Securities and Exchange Commission on June 14, 1996
Registration No. 33-44329
Registration No. 33-86920
Registration No. 33-80571
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________________
Amendment No. 2
to
FORM S-3
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
______________________________________________
SMT HEALTH SERVICES INC.
(Exact name of Registrant as specified in its charter)
Delaware 8093 25-1672183
(State or other jurisdiction (Primary standard industrial (I.R.S. employer
of incorporation) classification code number) identification number)
______________________________________________
Jeff D. Bergman, President
10521 Perry Highway SMT Health Services Inc.
Wexford, Pennsylvania 15090 10521 Perry Highway
(412) 933-3300 Wexford, Pennsylvania 15090
(412) 933-3300
(Address, including zip code, and (Name, address, including zip code,
telephone number, including area code, and telephone number, including area
of Registrant's principal executive offices) code, of agent for service)
______________________________________________
Copies to:
Ronald Basso, Esquire
Buchanan Ingersoll Professional Corporation
301 Grant Street, One Oxford Centre, 20th Floor
Pittsburgh, Pennsylvania 15219-1410
(412) 562-3943
_____________________________________________
Pursuant to Rule 429, this Registration Statement also serves as Post-
Effective Amendment No. 7 to Registration Statement No. 33-44329 and Post-
Effective Amendment No. 3 to Registration Statement No. 33-86920 (the "Prior
Registration Statements"). The prospectuses contained herein are combined
prospectuses covering 1,139,000 shares of Common Stock and 100,000 Warrants
registered under this Registration Statement and 2,355,623 shares of Common
Stock and 214,450 Warrants registered under the Prior Registration Statements.
Approximate date of commencement of proposed sale to public:
As soon as practicable after the Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, check the following box. [X]
The Registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Commission, acting pursuant to Section 8(a), may
determine.
================================================================================
<PAGE>
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
+Information contained herein is subject to completion or amendment. A +
+registration statement relating to these securities has been filed with the +
+Securities and Exchange Commission. These securities may not be sold nor may +
+offers to buy be accepted prior to the time the registration statement +
+becomes effective. This prospectus shall not constitute an offer to sell or +
+the solicitation of an offer to buy nor shall there be any sale of these +
+securities in any State in which such offer, solicitation or sale would be +
+unlawful prior to registration or qualification under the securities laws of +
+any such State. +
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Subject to Completion, June 14, 1996
PROSPECTUS
SMT HEALTH SERVICES INC.
3,494,623 Shares of Common Stock
This Prospectus relates to an aggregate offering of up to 3,494,623 shares
of the Common Stock, par value $.01 per share (the "Common Stock"), of SMT
Health Services Inc., a Delaware corporation ("SMT" or the "Company"), which may
be offered and sold from time to time. Of the 3,494,623 shares of Common Stock
offered hereby, 1,793,348 shares are being offered by the Company upon exercise
of warrants (the "Company Warrants"), and 126,000 shares of Common Stock may be
offered by Daniel Porush, Kenneth Greene and Jordan Belfort (collectively, the
"Stratton Transferees") upon exercise of a unit purchase option (the "Option")
originally held by Stratton Oakmont Inc. ("Stratton"), which Option was
subsequently transferred to the Stratton Transferees. Stratton also transferred
to the Stratton Transferees its right to acquire 120,000 warrants pursuant to
the Option (the "Stratton Warrants") and, therefore, its right to acquire an
additional 126,000 shares of Common Stock pursuant to the Stratton Warrants.
This prospectus also covers the additional 126,000 shares of Common Stock that
may be offered by the Stratton Transferees upon exercise of the Stratton
Warrants. (The Company Warrants include the Stratton Warrants.) Additionally,
this prospectus covers 433,900 shares of Common Stock that may be offered by
Jeff D. Bergman, Chairman, Chief Executive Officer and President of the Company;
460,775 shares of Common Stock that may be offered by Daniel Dickman, Executive
Vice President and a director of the Company; 75,000 shares of Common Stock
that may be offered by David Spindler, Senior Vice President of the Company;
17,500 shares of Common Stock that may be offered by David A. Zynn, Chief
Financial Officer/Treasurer of the Company; and 186,000 shares that may be
offered by Mark A. DeSimone, a former director of and former consultant to the
Company (including 40,000 shares that may be offered by L.M. Paul, his spouse);
100,000, 102,100 and 100,000 shares of Common Stock that may be offered by Alan
Novich, David Malone and Gerald Cohn, each a director of the Company; and 50,000
and 50,000 shares of Common Stock that may be offered by Commonwealth
Associates, the Company's former investment banking firm, and Andres V. Bello, a
principal of Commonwealth Associates, respectively. See "The Company" and "The
Offering." Company Warrants held by the MRI Partners (as defined in "The
Offering") and Messrs. Porush, Greene Belfort, Bergman and Dickman also have
been registered for resale by a separate prospectus.
The Common Stock is traded on the Nasdaq National Market under the symbol
SHED. On June 11, 1996, the closing sale price for the Common Stock, as quoted
in the Nasdaq National Market, was $10.125 per share. As of June 11, 1996,
there were 3,087,225 shares of Common Stock outstanding, including 564,575 of
the shares offered hereby. See "Risk Factors -- Shares Eligible for Future
Sale." If all of the Common Stock offered hereby were outstanding as of that
date, there would have been an aggregate of 6,015,173 shares of Common Stock
issued and outstanding.
If all of the shares of Common Stock offered hereby by the Company's
executive officers and directors were sold, such persons would not own outright
any shares of Common Stock and their beneficial interest in the Common Stock
would decrease from 33.5% to substantially less than 1%. See Risk Factors --
"Selling Stockholders."
The Company will not receive any of the proceeds from the sale of the
Common Stock by the Selling Stockholders. Expenses of this offering, estimated
at $40,000, are payable by the Company. See "Plan of Distribution."
The Securities offered hereby are speculative and involve a
substantial degree of risk. Prospective investors should carefully
consider the factors set forth under "Risk Factors."
________________________________
NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THIS OFFERING TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS PROSPECTUS
AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED
UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY, THE SELLING SHAREHOLDERS OR ANY
OTHER PERSON. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A
SOLICITATION OF AN OFFER TO PURCHASE ANY COMMON STOCK OTHER THAN THOSE TO WHICH
IT RELATES, NOR DOES IT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN
OFFER TO PURCHASE BY ANY PERSON IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL FOR
SUCH PERSON TO MAKE SUCH AN OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS
PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY
IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME
SUBSEQUENT TO THE DATE HEREOF.
________________________________
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
________________________________
The date of this Prospectus is _________________, 1996.
<PAGE>
AVAILABLE INFORMATION
SMT is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and, in accordance
therewith, files reports and other information with the Securities and
Exchange Commission (the "Commission"). Such reports and other
information can be inspected and copied at the Public Reference Section of
the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, and at
the Commission's regional offices at Northwestern Atrium Center, 500 West
Madison Street, Suite 1400, Chicago, Illinois 60661-2511, and Seven World
Trade Center, 13th Floor, New York, New York 10048. Copies of the reports
and other information can be obtained from the Public Reference Section of
the Commission, Washington, D.C. 20549, at prescribed rates.
SMT has filed with the Commission a Registration Statement under the
Securities Act of 1933, as amended, with respect to the Securities offered
by this Prospectus. As permitted by the rules and regulations of the
Commission, this Prospectus does not contain all of the information set
forth in the Registration Statement. For further information about SMT
and the Securities offered hereby, reference is made to the Registration
Statement and to the financial statements, exhibits and schedules filed
therewith. The statements contained in this Prospectus about the contents
of any contract or other document referred to are not necessarily
complete, and in each instance reference is made to the copy of such
contract or other document filed as an exhibit to the Registration
Statement, each such statement being qualified in all respects by such
reference. Copies of each such document may be obtained from the
Commission at its principal office in Washington, D.C., upon payment of
the charges prescribed by the Commission. Electronic registration
statements made through the Electronic Data Gathering, Analysis, and
Retrieval system are publically available through the Commission's Web
site (http://www.sec.gov).
INCORPORATION BY REFERENCE
The following documents filed by the Company with the Commission
pursuant to the Exchange Act are incorporated herein by reference: (a)
Annual Report on Form 10-K for the fiscal year ended December 31, 1995, as
amended by Amendment No. 1 thereto; (b) Quarterly Report on Form 10-Q for
the fiscal quarter ended March 31, 1996, as amended by Amendment No. 1
thereto; (c) Proxy Statement dated March 28, 1996 and (d) The description
of the Company's Common Stock contained in the registration statement on
Form 8-A.
All documents subsequently filed by the Company pursuant to Section
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of
this offering shall be deemed to be incorporated by reference in this
Prospectus and to be a part hereof from the respective date of filing of
each such document. Any statement contained in a document incorporated or
deemed to be incorporated by reference herein shall be deemed to be
modified or superseded for purposes of this Prospectus to the extent that
a statement contained herein or in any other subsequently filed document
which also is, or is deemed to be, incorporated by reference herein
modifies or supersedes such statement. Any such statement so modified or
superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Prospectus.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon written or oral request, a copy of any or
all of the documents incorporated by reference herein, other than certain
exhibits to such documents. Requests for such documents should be
directed to David A. Zynn, Chief Financial Officer, SMT Health Services
Inc., 10521 Perry Highway, Wexford, Pennsylvania 15090. The Company's
telephone number is (412) 933-3300.
2
<PAGE>
RISK FACTORS
The purchase of the Common Stock being offered hereby involves a high
degree of risk and substantial dilution. Prospective investors should
carefully consider, among other matters, the following risks and other
factors before making a decision to purchase the Securities.
Significant Leverage and Repayment Obligations
The Company's business is highly capital intensive. The Company has
financed the acquisition of all of its Mobile Magnetic Resonance Imaging
("MRI") equipment through capital leases and loans and as a result is
highly leveraged. At December 31, 1995, the Company's total liabilities
were approximately $17.9 million and its capital was approximately $5.4
million. At March 31, 1996, the Company's total liabilities were
approximately $20.1 million and its capital was approximately $5.9
million. The Company is therefore subject to the risks associated with
such substantial leverage, including the risk that cash flow may not be
adequate to make required payments on indebtedness. A decrease in
equipment utilization arising from, among other things, cancellation or
nonrenewal of contracts, equipment malfunctions, the inability to effect
prompt and timely repairs to equipment or a reduction in demand for the
Company's equipment or services could materially and adversely affect the
Company's ability to service its indebtedness.
The Company's monthly payments on its capital leases and other long-
term debt were approximately $550,000 as of March 31, 1996. Total
payments under the Company's capital lease obligations and other long-term
debt may equal or exceed minimum revenues receivable under the Company's
service contracts if such contracts are not renewed by healthcare
providers, if receivables are not collected by the Company on a timely
basis or if the number of scans or other services performed fails to meet
expected levels. In such case, the Company would be unable to meet its
debt service obligations, and would be in default under its various loan
and lease agreements.
As of December 31, 1995, the Company's current assets were
approximately $5.6 million and its current liabilities were approximately
$5.2 million, resulting in a working capital surplus of approximately
$400,000. At March 31, 1996, the Company's current assets were
approximately $5.2 million, and its current liabilities were approximately
$5.8 million resulting in a working capital deficit of $600,000. The
change in working capital since year end is primarily due to the
acquisition of a mobile MRI provider during the first fiscal quarter. Of
such liabilities, approximately $4.4 million and $4.9 million represented
the current portion of long-term debt and capital lease obligations as of
December 31, 1995 and March 31, 1996 respectively. There can be no
assurance that the Company's revenues will continue to be sufficient to
satisfy the increased lease payments or that such favorable terms will be
available in the future.
Equipment Maintenance, Service and Damage
All of the diagnostic imaging equipment utilized by the Company is
technologically sophisticated and complex, requires regular service and is
subject to unpredictable malfunctions and breakdowns. The Company
contracts with, and relies upon, the equipment manufacturer to provide
maintenance services on a prompt and timely basis. Because diagnostic
imaging equipment is technologically sophisticated, it is uncertain
whether and how quickly others could provide maintenance services if the
equipment manufacturers were unable or unwilling to do so. Consequently,
the Company's business might be adversely affected if the manufacturers
stopped providing maintenance services.
Substantially all of the Company's tangible assets consist of
diagnostic imaging equipment, including primarily specially designed
mobile MRI units. Generally, a mobile unit is moved several times a week
from one location to another, and there is always a risk that a traffic
accident or automotive breakdown will occur while the equipment is in
transit. Although the Company's equipment is insured against the risks of
damage in an accident, and the Company is insured for business
interruptions resulting from any damage to such equipment for the period
required to repair or replace the equipment, it may not be possible to
repair damaged equipment so that it will achieve its original level of
performance. Substitute or replacement equipment may be unavailable and
the quality of the potential replacement equipment unknown. In addition,
there is no assurance that the Company would receive sufficient insurance
proceeds following any damage to its equipment to fully compensate it for
the losses resulting from such damage or receive business interruption
insurance proceeds to compensate for lost business.
3
<PAGE>
Reimbursement of Health Care Costs
The Company receives payment directly from health care providers,
rather than from private insurers, other third party payors or
governmental entities, for its mobile MRI units. The Company's mobile
service contracts with its customers provide that the Company must be paid
within 30 days of providing its services and are not conditioned upon the
receipt of payment by the healthcare provider. Under current
reimbursement regulations, the Company is unable to bill the insurer or
the patient directly for services provided for hospital inpatients or
outpatients. Payment to health care providers by third party payors for
the Company's diagnostic services depends substantially upon such payors'
reimbursement policies. Consequently, those policies have a direct effect
on health care providers' ability to pay for the Company's services and
the Company's level of charges. Mounting concerns about rising health
care costs may cause more restrictive reimbursement policies to be
implemented in the future. Restrictions on reimbursements to health care
providers may affect such providers' ability to pay for the services
offered by the Company and could indirectly adversely affect the Company's
financial performance.
Other Reimbursement Matters
Many insurance companies, employers and other payors are increasing
their use of managed care plans such as health maintenance organizations
("HMOs") and preferred provider organizations ("PPOs") as a means of
controlling their healthcare costs. In addition to contracting with
selected healthcare providers to provide healthcare services, often at a
discount or on a capitation basis, such plans engage in strict utilization
review activities to more closely control the utilization of services by
their subscribers. There can be no assurance that the increased use of
managed care plans in the Company's service areas will not affect its
level of charges or the demand for its services.
Numerous changes have been made in governmental and commercial
insurance programs in recent years in an effort to reduce the extent to
which these third-party payors absorb increases in medical costs. Some
third-party payors have also experienced difficulties in meeting their
payment obligations whether on a timely basis or otherwise. In addition, a
number of bills proposing to regulate, control or alter the methods of
financing and delivering healthcare, including proposals for a national
health insurance program, have been discussed and introduced in Congress
and various state legislatures. Further, Congress has proposed
Medicare/Medicaid Reform which would limit increases in governmental
healthcare expenditures. The effect of any of these proposals or changes
by existing insurers in their reimbursement methodologies on the
healthcare industry and the Company cannot be determined at this time.
Availability of Equipment Financing; Timely Delivery of Equipment
Future acquisitions of equipment will be made pursuant to capital and
operating leases or purchase financing. Leases or loans for mobile MRI
equipment are generally in the original principal amount of approximately
$1.8 million to $2.2 million per unit, depending upon the type, features
and options of the diagnostic imaging equipment leased. The Company's
ability to expand is, therefore, tied to the availability of lease or
purchase financing. Although the Company has in the past been able to
procure lease and purchase financing, there can be no assurance that
lenders or equipment leasing companies will continue to enter into leases
or purchase financing with the Company.
The timely delivery of mobile MRI equipment is outside the control of
the Company and significant delays in delivery may materially and
adversely affect the Company. Such delays could arise from, among other
things, manufacturer and delivery delays.
4
<PAGE>
Government Regulation
General. The provision of diagnostic imaging services is subject to
a number of federal, state and local laws, regulations and rules, some of
which are very complex. Although the Company believes that it is
currently in compliance with applicable laws, regulations and rules, some
of such laws are broadly written and subject to little or no
interpretation by courts or administrative authorities. Hence, there can
be no assurance that a third party or governmental agency will not contend
that certain aspects of the Company's operations or procedures are not in
compliance with such laws, regulations or rules or that state agencies or
courts would interpret such laws, regulations and rules in the Company's
favor. The sanctions for failure to comply with such laws, regulations or
rules could be denial of the right to conduct business, significant fines
and/or criminal penalties. Additionally, an increase in the complexity or
substantive requirements of such laws, regulations or rules could
adversely affect the Company's business.
Certificate of Need. In addition, several states in which the
Company operates have certificate of need ("CON") laws and regulations
that control and regulate the establishment of healthcare facilities and
services and the acquisition and operation by hospitals and other
providers of major equipment such as MRI units and other diagnostic
imaging equipment. In several states in which the Company operates, a
hospital or the Company may need a CON before the Company can provide its
diagnostic imaging services. CON regulations could inhibit the expansion
of the Company's business.
Practice of Medicine. The establishment, marketing and operation of
the diagnostic imaging units are subject to laws prohibiting the practice
of medicine by non-physicians. The Company's employees provide only the
technical services relating to the diagnostic procedures (under the
supervision of licensed physicians) and the related non-medical
administrative support services. Professional medical services, such as
the reading of the diagnostic imaging studies and related diagnosis, are
separately provided by licensed physicians. The Company does not employ
any physicians to provide medical services. There can be no assurance,
however, that state authorities or courts will not determine that the
Company's services and/or relationships with providers constitute the
unauthorized practice of medicine by the Company.
Fraud and Abuse Laws. The Social Security Act and certain provisions
of state law provide civil and criminal penalties for persons who
knowingly and willfully solicit, pay, offer or receive any remuneration,
directly or indirectly, as an inducement to make a referral of a patient
for services or items for which payment may be made under the Medicare or
Medicaid programs. Often termed "fraud and abuse" or "anti-kickback"
laws, the provisions have been broadly interpreted by the courts.
The Office of Inspector General of the Department of Health and Human
Services ("HHS") has issued regulations specifying certain business
arrangements and payment practices involving providers or other entities,
such as the Company, which will not be considered prohibited activities.
Commonly termed "safe harbor regulations," the regulations set forth
certain standards which, if satisfied, will ensure that the arrangement
will not be subject to criminal prosecution or civil sanctions under the
fraud and abuse laws. Failure to satisfy the safe harbors in and of
itself does not render an arrangement illegal. The Company believes it is
in compliance with the safe harbor regulations applicable to its current
operations.
One principal focus of the fraud and abuse laws has been on
arrangements in which profit distributions are made by a partnership or
other business venture for health-related items or services to investors
who make or are otherwise in a position to influence referrals of Medicare
or Medicaid patients to the venture. Where such arrangements exist, a
question is raised as to whether the profit distributions are illegal
payments in exchange for referrals. Certain safe harbors set forth
criteria which, if met, will insure that investors in business ventures
for health-related items or services will not be subject to scrutiny under
the fraud and abuse laws.
One safe harbor protects profit distributions to investors made by
publicly traded companies with tangible assets of more than $50 million.
At present, the Company does not satisfy the asset threshold for
protection under this safe harbor.
5
<PAGE>
Another safe harbor covers investment interests in small entities.
The conditions for compliance with this safe harbor include, among other
things, requirements that no more than 40% of the investment interests of
each class of investments in the entity may be held by persons who are in
a position to make or influence referrals (including hospitals and
physicians), furnish items or services to the entity or otherwise generate
business for the entity, so-called "tainted investors," and that no more
than 40% of the entity's gross revenues may come from referrals, items or
services furnished or business otherwise generated by "tainted investors."
Unless a large percentage of the Company's Common Stock or Warrants are
held by "tainted investors," it would appear that investments in the
Company will fall within the safe harbor for investment interests.
None of the Company's mobile MRI activities are carried out through
partnerships or other ventures with hospitals, physicians or other third
parties.
The laws involving fraud and abuse and the safe harbor regulations
are currently in a rapid state of development and it is difficult to
provide a clear analysis of the risks in this area. There can be no
assurance that enforcement agencies or courts will determine that any
existing arrangements comply with all applicable laws and regulations.
Other Patient Referral Restrictions. Additionally, Pennsylvania, as
well as other states in which the Company operates, prohibits the referral
of Medicaid patients for services or items by a provider in which the
referring physician has an ownership interest. Certain states do not
restrict patient referrals but do require the disclosure to a patient by
the referring physician of a financial interest in a facility or vendor to
which the patient is being referred for services or items.
Stark II. The Omnibus Budget Reconciliation Act of 1993 enacted new
federal anti-referral legislation, more commonly known as "Stark II" after
its prime sponsor, Rep. Fortney "Pete" Stark (D. Calif.). Effective
January 1, 1995, Stark II bans referrals by physicians of Medicare and
Medicaid patients to entities for certain designated health services,
including MRI services, if a physician or immediate family member has a
prohibited financial relationship with the entity providing the service.
A financial relationship is generally defined as an ownership or
investment interest in or compensation arrangement with the entity,
subject to certain exceptions. Penalties include nonpayment for services
rendered pursuant to a prohibited referral, civil money penalties and
fines and possible exclusion from the Medicare and Medicaid programs. The
Company believes it is currently in compliance with the requirements of
Stark II. However, there can be no assurance that enforcement agencies or
courts will determine that existing arrangements comply with all
applicable laws and regulations.
Need for Additional Financing
The Company expects that its current cash balances, future cash flows
anticipated to be generated from operations and available equipment
financing arrangements will be sufficient to fund the Company's operations
through at least fiscal year 1997. This estimate is based on certain
assumptions, including the maintenance of expenses and cash flows from
operations at historical levels. There can be no assurance that these
assumptions will be realized or that a sufficient level of equipment
utilization will be attained to fund operations after the stated period.
The failure to achieve these assumptions may decrease the period of time
for which the Company estimates that these funds will be sufficient.
Reliance on Key Personnel
The Company's success depends in large part upon a number of key
management personnel and technical employees. The loss of the services of
one or more of its management personnel, in particular Jeff D. Bergman,
Daniel Dickman, David A. Zynn and David Spindler, could have a material
adverse effect on the Company. The Company has key man life insurance
covering Messrs. Bergman, Dickman and Spindler.
6
<PAGE>
The ability of the Company to attract and retain qualified
technicians to operate the diagnostic imaging equipment is crucial to the
operations of the Company. Such technicians are in short supply and are
typically attracted to nonmobile facilities which provide predictable
locations and work schedules. In contrast, mobile facilities provide very
unpredictable work schedules and constantly changing locations which may
not be attractive to a large portion of technicians. Therefore, the
Company may experience some difficulty finding qualified technicians for
its mobile MRI units. The Company believes its future success will depend
in part on its ability to attract and retain highly skilled employees. To
date, the Company has been able to attract sufficient technicians,
although there can be no assurance that this will continue in the future.
Technological Change and Obsolescence
The Company's services require the use of state-of-the-art medical
diagnostic equipment that has been characterized by rapid technological
advances. Although the Company believes that the equipment it provides
can be upgraded to maintain its state-of-the-art character, the
development of new technologies or refinements of existing ones might make
the Company's existing equipment technologically or economically obsolete,
or cause a reduction in the value of, or reduce the need for, the
Company's equipment. Diagnostic imaging equipment is currently
manufactured by numerous companies. Competition among manufacturers for a
greater share of the diagnostic imaging equipment market may have the
effect of generating greater technological advances in the capacity of
this new equipment. Consequently, the obsolescence of the Company's
equipment may be accelerated. Although the Company is aware of no
substantial technological change, should such change occur there can be no
assurance that the Company will be able to acquire the new or improved
equipment which may be required to service its customers.
Other Requirements Concerning Licensing, Permits and Approvals
Most states do not currently license MRI providers such as the
Company. Hospitals with which the Company has contracted are subject to a
variety of regulations and standards of state licensing and other
authorities and accrediting bodies such as the Joint Commission for the
Accreditation of Healthcare Organizations ("JCAHO"). As an outside
vendor, the Company may be required to comply with such regulations and
standards to enable the hospitals with which it has contracted to maintain
their permits, approvals and accreditations.
There can be no assurance that future changes in the laws and
regulations relating to the delivery of healthcare items and services may
require the Company or any venture involving the Company to obtain and
maintain certain governmental approvals for continued operations. It is
not possible to predict the effect of such changes in the law on the
Company at this time.
For the most part, the Company's employees need not have special
licenses. Drivers of trucks must have certain special driving licenses.
MRI technicians are not required to have licenses in any of the states in
which the Company does business. However, many states are holding
discussions to require such licensing and to require continuing education.
The Company believes that any such licensing requirement would not have
any adverse impact on the Company.
Competition
The healthcare industry in general, and the market for diagnostic
imaging services in particular, is highly competitive. Certain
competitors operate fixed-site centers and mobile units in the Company's
current service area. Some competitors may have financial resources
substantially greater than those of the Company which may give them
advantages in negotiating equipment acquisitions and responding quickly to
new demand or new technology. In addition, hospitals, private clinics and
radiology practices in the Company's service area have in-house equipment
which competes with the Company. MRI also competes with less expensive
diagnostic imaging devices and procedures which may provide similar
information to the physician. Existing healthcare providers who are
currently customers of the Company may purchase diagnostic imaging
equipment if the cost of such equipment decreases or if their volume of
patients increases to the point where it becomes cost-effective to own and
operate their own equipment.
7
<PAGE>
Insurance
The Company carries workers' compensation insurance, comprehensive
and general liability insurance, business interruption, fire and allied
perils coverage in amounts deemed adequate by the Company. The Company
requires that its healthcare customers maintain professional liability
insurance and the Company maintains its own professional liability policy.
There can be no assurance that claims will not exceed the amounts of
insurance coverage, that the cost for such coverage will not increase to
the extent that the Company will be forced to self-insure a substantial
portion of this risk, or that such coverage will not be reduced or become
unavailable.
Selling Stockholders
The selling stockholders of the Common Stock offered hereby include
Jeff D. Bergman, Chairman, Chief Executive Officer and President of the
Company, Daniel Dickman, Executive Vice President and a director of the
Company, David Spindler, Senior Vice President of the Company, and David
A. Zynn, Chief Financial Officer and Treasurer of the Company. Such
individuals comprise all of the executive officers of the Company. In
addition, the selling stockholders include all of the directors and one
former director of the Company. Each of such persons is offering for sale
all shares of Common Stock beneficially owed by such person (other than
51,000 shares issuable upon exercise of certain options held by employees,
directors and a former director). If all of the shares of Common
Stock offered hereby by such persons were sold, the executive officers and
directors of the Company would not own outright any shares of Common
Stock. As a result, management's and the directors' beneficial interest
in the Common Stock of the Company would decrease from approximately 33.5%
to substantially less than 1%.
Control of Company
The Company's officers and directors as a group beneficially own
approximately 33.5% of the Company's Common Stock and are able to exert
considerable influence over the affairs and policies of the Company.
Dividends
The Company has not paid, and does not anticipate paying in the
foreseeable future, cash dividends on its Common Stock.
On July 10, 1995, the Company paid a 5% stock dividend to all holders
of record of its Common Stock as of June 30, 1995.
Current Prospectus and State Registration Required to Exercise Warrants,
Possible Redemption of Warrants
Holders of the Company Warrants will be able to exercise such
warrants only if a current prospectus relating to the Common Stock
underlying the Company Warrants is then in effect and only if such Common
Stock is qualified for sale or exempt from qualification under the
applicable securities laws of the states in which the various holders of
Company Warrants reside. Although the Company will use its best efforts
to maintain the effectiveness of a current prospectus covering the Common
Stock underlying the Company Warrants, there can be no assurance that the
Company will be able to do so. The Company will be unable to issue Common
Stock to those persons desiring to exercise their Company Warrants if a
current prospectus covering the Common Stock issuable upon the exercise of
the Company Warrants is not kept effective or if such Common Stock is not
qualified nor exempt from qualification in the states in which the holders
of the Company Warrants reside. In November 1995, the Company's
securities began to trade on the Nasdaq National Market, and accordingly
there may be exemptions available in substantially all of the states. The
Company Warrants (other than the 126,000 Company Warrants held by the
Stratton Transferees upon exercise of the Option) are subject to
redemption by the Company at any time at $.05 per warrant on 30 days'
prior written notice if the closing bid price of the Common Stock shall
have averaged in excess of $9.53 per share (subject to adjustment) for 20
consecutive business days ending within 5 days of the date on which notice
of redemption is given. If the Company Warrants are redeemed, the warrant
holders will lose their right to exercise the Company Warrants except
during such 30-day redemption period. Redemption of the Company
8
<PAGE>
Warrants could force the holders to exercise the Company Warrants at a
time when it may be disadvantageous for the holders to do so or to sell
the Company Warrants at the then market value of the Company Warrants at
the time of redemption.
Shares Eligible for Future Sale
As of the date hereof, there were 3,087,225 shares of Common Stock
issued and outstanding, excluding 1,793,348 shares issuable by the Company
upon exercise of the Company Warrants, 126,000 shares of Common Stock
issuable to the Stratton Transferees upon exercise of an option, 100,000
shares issuable to Commonwealth Associates, the Company's former
investment banking firm, upon exercise of 100,000 warrants (the
"Commonwealth Warrants") and 949,100 shares issuable to certain officers
and directors upon exercise of options and rights held by them. Of such
3,087,225 shares of Common Stock, 1,449,000 shares of Common Stock were
sold in the IPO, 693,000 shares were sold by certain selling stockholders
pursuant to registration statements under the Securities Act of 1933, as
amended (the "Securities Act"), and 438,825 shares were issued pursuant to
the exercise of options under registration statements under the Securities
Act. The remaining 506,400 shares of Common Stock are "restricted
securities" (as that term is defined under Rule 144 promulgated under the
Securities Act) held by four (4) persons. The Company believes that all
but 120,000 of such shares have been held for at least two years and may
be sold in accordance with Rule 144. The sale, or availability for sale,
of substantial amounts of Common Stock in the public market, or any
additional offering of Common Stock, could adversely affect the prevailing
market price of the Common Stock and could impair the Company's ability to
raise additional capital through the sale of its equity securities.
Sale of Discontinued Operations
As previously disclosed in the Company's public filings, the Company
implemented a plan which it believed would lead to the divestiture of its
outpatient healthcare centers during 1994. On October 31, 1994, the
Company sold substantially all of the assets of its radiation therapy
center located in Auburn, Washington, for a total sale price of
approximately $1.3 million. The sale of the center did not result in a
gain or loss and resulted in cash proceeds to the Company of $400,000.
The Company remains obligated on approximately $400,000 of capital leases
as of March 31, 1996. The buyer has agreed to use its best efforts to
have the Company released from these leases and has secured its
obligations to the Company to perform these leases through a pledge of
certain assets in favor of the Company.
On June 30, 1995, the Company completed the sale of substantially all
of the assets of its remaining outpatient healthcare center, Airport
Regional Imaging Center, located in Coraopolis, Pennsylvania, as well as
its sixty percent ownership and general partner interests in all of its
cardiac care centers to Cardiac Fitness Inc., or an affiliate thereof, for
a total sale price of approximately $600,000, including cash and net trade
receivables of approximately $500,000 and a note of $100,000. Although
the buyer assumed all future operating liabilities of the healthcare
center, the Company remains obligated on approximately $700,000 of capital
leases as of March 31,, 1996. The buyer has agreed to use its best
efforts to have the Company released from these leases and has secured its
obligations to the Company to perform these leases through a pledge of
stock and certain assets in favor of the Company.
The sale of the healthcare center, which had previously been treated
as a discontinued operation, did not result in a gain or loss. The sale
of the sixty-percent ownership and general partnership interests in the
cardiac care centers which were treated as continuing operations, resulted
in an approximate $50,000 pre-tax gain which was recorded in the second
quarter of 1995.
________________________________
Although it will have no legal obligation to do so, any underwriter
participating in this offering may, from time to time, act as a market
maker or otherwise effect transactions in the Company's securities. Such
underwriter, or other underwriters participating in the offering, if any,
may be dominating influences in the market for the Securities. The price
and liquidity of the Securities may be affected by the degree, if any, of
such underwriter
9
<PAGE>
participation in the market. Such activities, if commenced, may be
discontinued at any time or from time to time and may require the Company
to establish new market makers.
________________________________
The Company will furnish to holders of its Common Stock annual
reports containing audited financial statements. The Company may also
distribute quarterly reports containing unaudited financial information
for the first three quarters of each fiscal year.
10
<PAGE>
THE COMPANY
The Company is primarily engaged in the business of operating
mobile MRI units. MRI involves the use of high strength magnetic fields
and radio waves to produce cross-sectional images of the anatomy. MRI
facilitates the diagnosis in the early stages of disease without the need
for exploratory surgery or other invasive procedures. MRI has become a
preferred diagnostic tool of the medical profession because it is non-
invasive and its images are generally better defined and more precise than
those produced by other diagnostic imaging tests, without the use of
harmful ionizing radiation, such as that produced by computed axial
tomography ("CAT") scans and standard x-rays.
The Company provides mobile MRI services to healthcare
providers, which consist primarily of small and medium size hospitals.
Including a new MRI unit acquired in February 1996 and the purchase of two
new units from another mobile provider in March 1996, the Company
currently operates fourteen mobile MRI units which service healthcare
providers located in Pennsylvania, North Carolina, West Virginia, Ohio,
Virginia and Kentucky. The MRI equipment is transported in specially
designed vans that are driven to the healthcare provider's facility where
the imaging occurs. The healthcare provider pays the Company on a per
scan basis for the use of the equipment. The healthcare providers
utilizing the Company's services have a need for MRI services, but do not
own their own equipment due to insufficient patient volume to justify a
full-time fixed MRI unit, the high cost of owning and operating such
equipment, the lack of expertise in this highly specialized field or due
to regulatory constraints.
The Company was formed in November 1991 to merge with Shared
Medical Technologies, Inc., a Pennsylvania corporation incorporated in
1987 ("Old SMT") and Shared MRI-4, Inc., a Pennsylvania corporation ("MRI-
4"), and to acquire substantially all of the assets and assume
substantially all of the liabilities of Shared MRI-1, L.P., a Pennsylvania
limited partnership ("MRI-1") and Shared MRI-3, L.P., a Pennsylvania
limited partnership ("MRI-3") (Old SMT, MRI-4, MRI-1 and MRI-3 are
collectively referred to as the "SMT Group"), each of which leased one,
and in the case of Old SMT, two, mobile MRI units (the "Consolidation").
As of November 1991, all of the four entities comprising the SMT Group
were owned or controlled by Jeff D. Bergman, Daniel Dickman and Mark A.
DeSimone, who (along with Mr. DeSimone's wife) are holders of 564,575
shares, or approximately 18%, of the Company's outstanding Common Stock.
Messrs. Bergman, Dickman and DeSimone in the aggregate are beneficial
owners of an additional 538,500 shares through rights to acquire the
Company's Common Stock. The assets of MRI-1 and MRI-3 were acquired by
the Company in exchange for an aggregate of $1,300,000 in notes (the "LP
Notes"), the assumption of approximately $2,600,000 of liabilities of the
partnerships (primarily relating to the capital leases for the MRI
equipment) and 99,950 Warrants. In March 1992, the LP Notes were
redeemed, utilizing a portion of the net proceeds of the IPO.
In March 1992, the Company effectuated an underwritten initial
public offering (the "IPO") of Units, each Unit consisting of one share of
Common Stock and one Company Warrant to purchase a share of Common Stock
for $7.00 (subsequently adjusted to $6.67 as a result of a stock
dividend). The Units traded on Nasdaq from March 4, 1992, until October
15, 1992. On October 16, 1992 (the "Separation Date"), the Common Stock
and Company Warrants began to trade separately on Nasdaq under the symbols
"SHED" and "SHEDW," respectively, and the Units were delisted from trading
on Nasdaq.
During November 1995, the Company's Common Stock and Company
Warrants began to trade on the Nasdaq National Market under the symbols
SHED and SHEDW, respectively.
The Company's executive offices are located at 10521 Perry
Highway, Wexford, Pennsylvania 15090, and its telephone number is (412)
933-3300. Unless the context requires otherwise, with respect to events
occurring prior to the Consolidation, the "Company" may refer to one or
more of the entities comprising the SMT Group.
11
<PAGE>
THE OFFERING
1. 1,793,348 shares of Common Stock are being offered by the
Company upon exercise of the Company Warrants (includes 126,000 shares
shown in 2(b) below that, alternatively, may be offered by the Stratton
Transferees, 2,100 shares shown in 3 below that may be issued to and re-
offered by Mr. Bergman). The Company Warrants were issued in the following
transactions:
(a) 1,380,000 Company Warrants to purchase 1,449,000 shares of
Common Stock were issued as part of the Units offered by
the Company in the IPO.
(b) 99,950 Company Warrants to purchase 104,948 shares of
Common Stock that were originally issued to the former
Limited Partners of MRI-1 and MRI-3 (the "MRI Partners") as
partial consideration for the assets of MRI-1 and MRI-3.
See "The Company."
(c) 120,000 Stratton Warrants to purchase 126,000 shares of
Common Stock are issuable upon exercise of the Unit
Purchase Option (the "Option") issued in the IPO to
Stratton, the underwriter of the IPO and subsequently
transferred to the Stratton Transferees. The Option is
exercisable for 126,000 shares of Common Stock and 120,000
Warrants to purchase 126,000 shares of Common Stock.
(d) 108,000 Company Warrants to purchase 113,400 shares of
Common Stock that were originally issued to DVI Financial
Services Inc., an affiliate of the Company ("DVI"),
pursuant to the conversion of the Series A Preferred Stock.
DVI sold such 108,000 Company Warrants pursuant to an
effective registration statement under the Securities Act
of 1933, as amended (the "Securities Act").
2. 252,000 shares of Common Stock may be offered by the Stratton
Transferees as follows:
(a) 126,000 shares of Common Stock upon exercise of the Option
described in 1(c) above; and
(b) 126,000 shares of Common Stock upon exercise by the
Stratton Transferees of the 120,000 Stratton Warrants
(shown also in 1(c) above) receivable upon exercise of the
Option.
3. 433,900 shares of Common Stock may be offered by Jeff D.
Bergman, including 40,000 shares which Mr. Bergman beneficially owns
through a partnership, 96,500 shares which Mr. Bergman has the right to
acquire at various prices ranging from $2.46 to $3.8125 through the
exercise of stock options pursuant to the Company's 1991 Employee Stock
Option Plan, 100,000 shares which Mr. Bergman has the right to acquire at
$3.875 pursuant to a grant of 100,000 warrants under the Company's 1995
Director Warrant Plan (the "Director's Warrants") and 2,100 shares which
Mr. Bergman has the right to acquire by exercise of the 2,000 Company
Warrants acquired by him in open market transactions (see "Certain
Relationships").
4. 460,775 shares of Common Stock may be offered by Daniel Dickman,
including 40,000 shares which Mr. Dickman beneficially owns through a
partnership, 71,500 shares which Mr. Dickman has the right to acquire at
various prices ranging from $3.33 to $3.8125 through the exercise of stock
options pursuant to the Company's 1991 Employee Stock Option Plan, and
100,000 shares which Mr. Dickman has the right to acquire at $3.875
pursuant to a grant of 100,000 Director's Warrants (see "Certain
Relationships").
5. 186,000 shares of Common Stock may be offered by Mark A.
DeSimone, including 31,500 shares which Mr. DeSimone has the right to
acquire at $1.875 by exercise of options granted to him by the Company for
services rendered, 40,000 shares of Common Stock held by L.M. Paul, his
spouse, which shares may be deemed to be beneficially owned by him (Mr.
DeSimone disclaims beneficial ownership of such shares) and
12
<PAGE>
114,500 shares which Mr. DeSimone has the right to acquire at $4.01
pursuant to a grant of 114,500 warrants by the Board of Directors.
6. 100,000 shares of Common Stock may be offered by Alan Novich,
including 100,000 shares which Mr. Novich has the right to acquire at
$3.875 pursuant to a grant of 100,000 Director's Warrants.
7. 102,100 shares of Common Stock may be offered by David A.
Malone, including 100,000 shares which Mr. Malone has the right to acquire
at $3.875 pursuant to a grant of 100,000 Director's Warrants and 2,100
shares which Mr. Malone has the right to acquire at $1.875 by exercise of
options granted for services rendered.
8. 100,000 shares of Common Stock may be offered by Gerald Cohn,
which shares Mr. Cohn has the right to acquire at $3.875 pursuant to a
grant of 100,000 Director's Warrants.
9. 75,000 shares of Common Stock may be offered by David Spindler,
which shares Mr. Spindler has the right to acquire at various prices
ranging from $2.46 to $3.8125 through the exercise of stock options
pursuant to the Company's 1991 Employee Stock Option Plan.
10. 17,500 shares of Common Stock may be offered by David A. Zynn,
which shares Mr. Zynn has the right to acquire at a price of $3.8125
through the exercise of stock options pursuant to the Company's 1991
Employee Stock Option Plan.
11. 40,000 shares of Common Stock may be offered by L.M. Paul, who
may be an affiliate of the Company by virtue of the fact that she is the
spouse of Mark A. DeSimone, a former director and former consultant to the
Company. These 40,000 shares are also shown in 5 above.
12. 50,000 warrants to purchase 50,000 shares of Common Stock at an
initial exercise price of $4.47 issued to each of Commonwealth Associates,
the Company's former investment banker and Andres V. Bello, Managing
Director, of Commonwealth Associates (the "Commonwealth Warrants"). 50,000
shares of Common Stock may be offered by each of Commonwealth Associates
and Andres V. Bello upon exercise of their respective Commonwealth
Warrants.
USE OF PROCEEDS
If all of the Company Warrants are exercised, the net proceeds to the
Company from the sale of the Common Stock offered by the Company pursuant
to the Company Warrants are estimated to be approximately $11,900,000. To
the extent that the Company receives any proceeds from the exercise of the
Company Warrants, the Company expects that such proceeds would be used to
continue to expand the business of the Company and for general working
capital purposes. However, there can be no assurance that all, if any, of
such Company Warrants will be exercised. The Company will not receive any
proceeds from the sale of shares of Common Stock by the selling
stockholders.
13
<PAGE>
SELLING STOCKHOLDERS
For a description of the manner in which the Common Stock offered
hereby by each of the selling stockholders (the "Selling Stockholders")
was acquired, and as to which shares are beneficially owned pursuant to
rights to acquire, see "The Offering." See the disclosure following this
table for information regarding any position, office or material
relationship that each of the Selling Stockholders has had with the
Company during the past three years.
The following table sets forth information with respect to the
beneficial ownership of Common Stock by each Selling Stockholder as of the
close of business on June 11, 1996, which may be offered from time to time
hereby. Unless indicated below, the address of each selling stockholder
is c/o SMT Health Services Inc., 10521 Perry Highway, Wexford,
Pennsylvania 15090. As a registered broker-dealer and market-maker in the
Common Stock and Warrants, Commonwealth Associates may, from time to time,
acquire and dispose of beneficial ownership of other Company securities.
As of the date of this Prospectus, assuming the sale by each of the
Selling Shareholders of all of the shares of Common Stock listed below,
the Company believes that none of such Selling Shareholders would
beneficially own any shares of Common Stock, Company Warrants, Stratton
Warrants, Director's Warrants or Commonwealth Warrants, except for shares
that may be acquired under the 1991 Employee Stock Option Plan or the
Stock Option Plan for Nonemployee Directors (see notes 1 and 2
below).
<TABLE>
<CAPTION>
Beneficial Ownership Prior to the Offering
------------------------------------------
Name of Selling Stockholder Number of Shares Percentage of Class
--------------------------- ---------------- -------------------
<S> <C> <C>
Jeff D. Bergman/1/ 433,900 13.2
Daniel Dickman/1/ 460,775 14.1
Mark A. DeSimone/2/ 186,000 5.7
L.M. Paul 40,000 1.3
Alan Novich 100,000 3.1
David J. Malone/2/ 102,100 3.2
Gerald Cohn/2/ 100,000 3.1
David Spindler/1/ 75,000 2.4
David A. Zynn/1/ 17,500 *
Daniel Porush 63,000 2.0
100 Rodeo Drive
Syosset, New York 11791
Kenneth Greene 50,400 1.6
c/o Stratton Oakmont, Inc.
1978 Marcus Avenue, Suite 120
Lake Success, New York 11042
Jordan Belfort 138,600 4.3
5 Pin Oak Court
Old Brookville, New York 11545
Andres V. Bello/3/ 100,000 3.1
c/o Commonwealth Associates
733 Third Avenue
New York, New York 10017
Commonwealth Associates 50,000 1.6
733 Third Avenue
New York, NY 10017
</TABLE>
____________________
/*/Less than 1%.
/1/Does not include, for Messrs. Bergman, Dickman, Spindler and Zynn,
7,000, 7,000, 3,000 and 2,500 shares, respectively, which such person has
the right to acquire under options issued to him under the Company's 1991
Employee Stock Option Plan.
/2/Does not include, for each of Messrs. DeSimone and Cohn, 8,400 shares
of Common Stock and, for Mr. Malone, 2,100 shares of Common Stock, which
each has the right to acquire under options issued to him under the
Company's Stock Option Plan for Nonemployee Directors.
/3/Includes 50,000 shares owned by Commonwealth Associates which Mr. Bello
may be deemed to beneficially own as a Managing Director of Commonwealth
Associates.
14
<PAGE>
The following sets forth information regarding any position, office
or material relationship that each of the Selling Stockholders has had
with the Company during the past three years.
Mr. DeSimone, a former director of the Company, was a consultant to
the Company and the Company, in 1991, entered into a five-year consulting
agreement with him pursuant to which he was entitled to receive a
consulting fee of $75,000 per annum. Mr. DeSimone provided services
relating to special projects and other business affairs of the Company.
The Company believes that the terms of this consulting agreement were as
favorable, in all material respects, as might have been obtained from an
unaffiliated third party. This agreement is scheduled to terminate in
November 1996. On March 27, 1996, the Company prepaid the remaining
$50,000 due under the agreement and terminated the consulting
relationship. Mr. DeSimone also was a partner in the law firm that
provided services to the Company in 1993. That law firm did not provide
legal services to the Company during 1994 or 1995 nor is it expected to
perform legal services in the future.
Messrs. Bergman (Chairman, Chief Executive Officer and President of
the Company), and Dickman (Chief Operating Officer and a director of the
Company) each owned a one-third equity interest in a partnership, Shared
Mobile Enterprises ("SME"), which leased and subleased to the Company
certain tractors for the transportation of mobile MRI units. The
remaining one-third interest in SME is owned by L.M. Paul. Ms. Paul is
Mark A. DeSimone's spouse. SME received a lease payment of approximately
$2,500 per month plus reimbursement of expenses from the Company for each
tractor. At December 31, 1993, 1994 and as of June 30, 1995, the Company
was leasing ten, ten and eleven tractors, respectively, from SME. During
1993, 1994 and 1995, lease payments to SME were approximately $258,000,
$257,000 and $180,000, respectively. The Company believes that the terms
of its leases with SME were as favorable, in all material respects, as
might have been obtained from an unaffiliated third party.
Effective July 1, 1995, SME released the Company from its obligations
under ten long term subleases in exchange for the issuance to SME of
120,000 unregistered shares of Common Stock valued at $3 per share, the
weighted average closing price for the stock for the prior thirty trading
days. The Company received an opinion from an independent financial
advisor that the transaction was fair to the Company and its stockholders.
At the same time, with the concurrence of the third party leasing company,
the Company assumed SME's obligations under its original lease and
modified that lease by (1) extending the lease term by one additional year
and (2) adding one additional truck cab to the schedule of leased property
with a corresponding increase in base rental payments. The $360,000 value
of the shares represents the present value of the excess of the sublease
payments over the original lease payments. The Company has capitalized
the $360,000 and is amortizing this prepaid rent over a period which
approximates the lease term. .
The Company has entered into numerous leasing transactions with DVI,
Inc. ("DVI"), although it is not anticipated that the Company will obtain
its future lease financing from DVI.
During 1992 and 1993, the Company entered into numerous leasing
transactions with DVI pertaining to both continuing and discontinued
operations involving total financing of approximately $15.6 million.
During 1994, the Company did not enter into any new leases with DVI and
refinanced with third parties $3.2 million of leases held by DVI. During
the first quarter of 1995, the Company refinanced its remaining leases
with DVI, totalling approximately $6.5 million, with third-party lease
companies. At December 31, 1994, the total cost and accumulated
amortization of equipment under capital lease obligation with DVI were
approximately $10.1 million and $3.3 million, respectively. Interest
rates under financing agreements with DVI ranged from 11% to 14%. Total
payments to DVI during 1993, 1994 and 1995 with respect to capital lease
obligations were approximately $4.1 million, $3.9 million and $.4 million,
respectively, including $1.7 million, $1.4 million and $.1 million
respectively, of interest expense associated with such capital leases.
Several leases with DVI were sold or assigned by DVI to third parties to
whom the Company directly makes monthly lease payments.
In February 1992, the Company acquired the assets and liabilities of,
or merged with, several predecessor entities (the "Consolidation"). In
connection with the Consolidation, DVI purchased, for an aggregate
purchase price of $600,000, the 368,000 shares of Common Stock previously
offered and 5,400 shares of the Company's Series A
15
<PAGE>
Preferred Stock. DVI's 5,400 shares of Series A Preferred Stock were
convertible into 108,000 shares of Common Stock. In order to facilitate
the IPO, the Company agreed to contribute to DVI 108,000 Warrants (if DVI
converted the Series A Preferred Stock and sold the Common Stock prior to
the date of separation of the Common Stock and Warrants (the "Separation
Date")) in order to allow DVI to sell the 108,000 Common Shares and
Warrants as Units during the period in which the Common Stock and Warrants
sold as Units and there was no established trading market for Common Stock
or Warrants separately. As of August 1, 1992, the Company and DVI agreed
that, in exchange for a reduction in the dividend rate of the Series A
Preferred Stock from 12% to 8%, the Company would deliver to DVI, upon
conversion of the 5,400 shares of Series A Preferred Stock, the 108,000
Warrants whether such conversion occurred before or after the Separation
Date. The Separation Date occurred on October 16, 1992. DVI also had
certain registration rights with respect to such shares of Common Stock
and Warrants. In July 1993, DVI converted the Series A Preferred Stock to
108,000 shares of Common Stock, SMT delivered 108,000 Warrants to DVI, and
DVI sold such shares and Warrants. In March 1995, DVI sold its 368,000
shares, pursuant to registration statements under the Securities Act of
1933, as amended (the "Securities Act").
In connection with DVI's investment in the Company, the Company has
agreed that DVI shall have the exclusive right, but not the obligation, to
lease or otherwise to finance the Company's acquisition of medical
diagnostic and therapeutic equipment for a period of five years ending
February 1997, provided that the terms and conditions charged to the
Company on such transactions are not greater than (a) the differentials
between the interest rates and such other terms and conditions on
transactions previously entered into by DVI with the Company; or (b) the
differentials between such terms and conditions generally applicable to
transactions entered into by DVI with other entities in which DVI or
principals of DVI have made equity investments structured in a manner
substantially similar to the structure of the investment made by DVI in
the Company. DVI has terminated its exclusive right to finance or
refinance the Company's leases.
In connection with DVI's participation in the Consolidation and its
investment in the Company, DVI agreed that, unless the Company otherwise
consented, neither DVI nor any of its affiliates would acquire 15% or more
of the capital stock of any entity if (i) such entity is engaged in the
business of operating diagnostic imaging equipment or radiation therapy
equipment (ii) such entity has its principal place of business in
Kentucky, Maryland, Michigan, Missouri, North Carolina, Ohio,
Pennsylvania, Virginia or West Virginia; and (iii) the equity investment
in such entity is made by DVI with the express agreement and understanding
that a public offering of the common stock of such entity will be made
within a reasonable period of time following he making of such investment
of DVI. The agreements with DVI do not, however, prohibit DVI from
competing with the Company and, in fact, DVI is and will continue to be a
direct competitor of the Company in connection with certain of DVI's
business activities. DVI will also compete with the Company as part of
its equipment leasing operations as well as through its acquisition of
interest in entities which may compete with the Company.
Gerald Cohn, a director of the Company, is a director and stockholder
of and consultant to DVI.
The Company signed a six-month agreement retaining Commonwealth
Associates ("Commonwealth") as its investment banking firm. Commonwealth,
a New York based investment banking firm specializing in serving the
financial needs of emerging growth companies, was engaged to assist the
Company in establishing a long-term financial strategy and in evaluating
possible transactions involving other mobile diagnostic providers. In
addition to a normal retainer, the Company granted to Commonwealth 100,000
five-year warrants to purchase the Company's Common Stock at $4.47, the
closing bid price of the Common Stock the day the Agreement was executed.
This Agreement with Commonwealth expired on April 10, 1996.
In March 1995, the Company entered into a five-year employment
agreement with each of Jeff D. Bergman and Daniel Dickman, pursuant to
which Mr. Bergman agreed to serve as the Chairman of the Board, President
and Chief Executive Officer of the Company and Mr. Dickman as the
Executive Vice President and Chief Operating Officer, each at an annual
base salary of not less than $180,000. The employment agreements provide
that if the employee is terminated other than for "cause" or if the
employee terminates for "good reason" (including a change in control
event), the employee shall be entitled to a continuation of full salary
and bonus compensation for a period equal to the remainder of the term.
The agreements further provide for a lump sum payment of two and one-half
times salary, bonus and certain other amounts and continuation of certain
benefits in the event that the employee is terminated in connection with a
change in control of the Company. Both contracts provide for annual
profit sharing
16
<PAGE>
with other executive level employees of a bonus pool consisting of 15% of
the Company's consolidated income before taxes, determined in accordance
with generally accepted accounting principles for financial reporting
purposes. Each of these Executive Officers received approximately $74,000
pursuant to the bonus pool for services rendered in 1995.
Stratton was the underwriter of the Company's initial public
offering. In connection with the initial public offering, Stratton
received underwriting commission of $690,000, an expense allowance of
$207,000, and certain indemnifications.
As additional compensation in connection with the initial public
offering, the Company granted to Stratton the Option which covers 120,000
units, each unit consisting of 1.05 shares of Common Stock and one Company
Warrant to purchase 1.05 shares of Common Stock. The Option is
exercisable until March 4, 1997 and entitles Stratton to purchase each
unit at an exercise price equal to $5.94, subject to adjustment in certain
events. Stratton subsequently transferred the Option to the Stratton
Transferees, who are selling stockholders.
On August 9, 1995, the Company adopted the 1995 Director Warrant
Plan (the "Plan") pursuant to which eligible directors received
unregistered Director's Warrants. The Plan allows for issuance of
Director's Warrants to purchase up to 700,000 shares of Common Stock.
On August 9, 1995, Director's Warrants to purchase up to 500,000
shares of Common Stock at an initial exercise price of $3.875, the closing
price of the Company's stock on the date of issue, were issued to five
directors. Separately, unregistered warrants to purchase 114,500 shares of
Common Stock at an initial exercise price of $4.01 were also issued to an
outside director, who was also a consultant to the Company, who was
ineligible to participate in the Plan.
PLAN OF DISTRIBUTION
The Company has been advised that the Common Stock offered by the
Selling Stockholders (the "Shares") may from time to time be offered and
sold by the Selling Stockholders to or through underwriters, through one
or more agents or dealers or directly to purchasers. The distribution of
the Shares may be effected from time to time in one or more transactions
at a fixed price or prices, which may be changed, at market prices
prevailing at the time of sale, at prices related to such prevailing
market prices or at negotiated prices. The Company has been further
advised that offers to purchase Shares may be solicited directly by the
Selling Stockholders or by agents designated by the Selling Stockholders
from time to time.
If sold through agents, the Shares may be sold from time to time by
means of (i) ordinary brokers' transactions, (ii) block transactions
(which may involve crosses) in accordance with the rules of any stock
exchange or trading system on which the Common Stock is admitted for
trading privileges (the "Markets"), in which such an agent may attempt to
sell the Common Stock as agent but may position and resell all or a
portion of the blocks as principal, (iii) "fixed price offerings" off the
Markets (as described below) or (iv) any combination of such methods of
sale, in each case at market prices prevailing at the time of sale in the
case of transactions on the Markets and at prices related to prevailing
market prices or negotiated prices in the case of transactions off the
Markets. In connection therewith, distributors' or sellers' commissions
may be paid or allowed. If an agent purchases Shares as principal, such
stock may be resold by any of the methods of sale described above.
17
<PAGE>
<PAGE>
From time to time an agent may conduct a "fixed price offering" of
Shares off the Markets. In such case, such agent would purchase a block
of shares from the Selling Stockholders and would form a group of selected
dealers to participate in the resale of the shares.
If a dealer is utilized in the sale of Shares, the Selling
Stockholders may sell such Shares to the dealer as principal. The dealer
may then resell such Shares to the public at varying prices determined by
such dealer at the time of resale.
In connection with the sale of Shares, underwriters or agents may
receive compensation from the Selling Stockholders or from purchasers of
Shares for whom they may act as agents in the form of discounts,
concessions or commissions. Underwriters or agents may sell Shares to or
through dealers, and such dealers may receive compensation in the form of
discounts, concessions or commission from the underwriters or agents
and/or commissions from the purchasers for whom they may act as agents.
Underwriters, agents and dealers that participate in the distribution of
Shares may be deemed to be underwriters, and any discounts or commissions
received by them from the Selling Stockholders and any profit on the
resale of Shares by them may be deemed to be underwriting discounts and
commissions, under the Securities Act of 1933, as amended ("Securities
Act").
Under agreements which may be entered into by the Company and the
Selling Stockholders, underwriters and agents who participate in the
distribution of Shares may be entitled to indemnification by the Selling
Stockholders and the Company against certain civil liabilities, including
liabilities under the federal securities laws, or to contribution by the
Selling Stockholders and the Company to payments which such underwriters
or agents may be required to make in respect thereof. Underwriters,
agents and dealers may engage in transactions with or perform services for
the Selling Stockholders and/or the Company in the ordinary course of
business.
EXPERTS
The financial statements and the related financial statement
schedules incorporated in this Prospectus by reference from the Company's
Annual Report on Form 10-K, as amended by Amendment No. 1 thereto, as of
and for the years ended December 31, 1995 and December 31, 1994, have been
audited by KPMG Peat Marwick LLP; and for the year ended December 31, 1993
have been audited by Deloitte & Touche LLP, independent auditors, as
stated in their respective reports which are incorporated herein by
reference, and have been so incorporated in reliance upon the reports of
such firms given upon their authority as experts in accounting and
auditing.
Certain legal matters with respect to the shares of Common Stock
offered hereby have been passed upon for the Company by Buchanan Ingersoll
Professional Corporation.
18
<PAGE>
Subject to Completion, dated June 14, 1996
PROSPECTUS
SMT HEALTH SERVICES INC.
214,450 Warrants
This Prospectus relates to an aggregate offering of up to 214,450
warrants (the "Warrants") to purchase common stock, par value $.01 per share
(the "Common Stock"), of SMT Health Services Inc., a Delaware corporation ("SMT"
or the "Company"). Of the Warrants offered hereby, 92,450 of such Warrants are
being offered by the former Limited Partners of Shared MRI-1, L.P. and Shared
MRI-3, L.P., Pennsylvania limited partnerships (the "L.P. Holders"), and 120,000
Warrants (the "Stratton Warrants") may be offered by Daniel Porush, Kenneth
Greene and Jordan Belfort (the "Stratton Transferees") upon exercise of a unit
purchase option (the "Option") originally held by Stratton Oakmont Inc.
("Stratton") which was subsequently transferred to the Stratton Transferees; and
2,000 Warrants may be offered by Jeff D. Bergman, Chairman, Chief Executive
Officer and President of the Company. The L.P. Holders, the Stratton Transferees
and Mr. Bergman are referred to herein as the "Selling Stockholders." See
"Selling Stockholders." The Warrants (other than the Stratton Warrants held by
the Stratton Transferees upon exercise of the Option) are redeemable by the
Company in certain events. Each Warrant, entitles the holder thereof to purchase
1.05 shares of Common Stock for $6.67 per share, subject to adjustment in
certain events, at any time until 5:00 p.m., Eastern Time, on March 4, 1997,
unless previously redeemed by the Company.
The Warrants and the Common Stock are traded on the Nasdaq National
Market under the symbols SHEDW and SHED, respectively. The closing sale price,
as quoted in the National Market for the Warrants was $3.375 per Warrant on June
11, 1996, and for the Common Stock was $10.125 per share on June 11, 1996.
The Company will not receive any of the proceeds from the sale of
the Warrants by the Selling Stockholders. Expenses of this offering, estimated
at $40,000, are payable by the Company. See "Plan of Distribution."
Reference is hereby made to and prospective investors should
consider the concurrent offering of the Company's Common Stock through which
substantially all of the Common Stock beneficially owned by the Company's
directors and executive officers is registered for sale. Such offering is being
made through a separate prospectus which is available from the Company on
request. See "The Company."
The Warrants offered hereby are speculative and involve a
substantial degree of risk. Prospective investors should carefully consider the
factors set forth under "Risk Factors."
NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THIS OFFERING TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS PROSPECTUS AND,
IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS
HAVING BEEN AUTHORIZED BY THE COMPANY, THE SELLING STOCKHOLDERS OR ANY OTHER
PERSON. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION
OF AN OFFER TO PURCHASE ANY WARRANTS OTHER THAN THOSE TO WHICH IT RELATES, NOR
DOES IT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO PURCHASE BY
ANY PERSON IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL FOR SUCH PERSON TO MAKE
SUCH AN OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY
SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT
THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE
DATE HEREOF.
------------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
------------------------------
The date of this Prospectus is , 1996.
-----
<PAGE>
AVAILABLE INFORMATION
SMT is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and, in accordance
therewith, files reports and other information with the Securities and Exchange
Commission (the "Commission"). Such reports and other information can be
inspected and copied at the Public Reference Section of the Commission at 450
Fifth Street, N.W., Washington, D.C. 20549, and at the Commission's regional
offices at Northwestern Atrium Center, 500 West Madison Street, Suite 1400,
Chicago, Illinois 60661-2511, and Seven World Trade Center, 13th Floor, New
York, New York 10048. Copies of the reports and other information can be
obtained from the Public Reference Section of the Commission, Washington, D.C.
20549, at prescribed rates.
SMT has filed with the Commission a Registration Statement under the
Securities Act of 1933, as amended, with respect to the Securities offered by
this Prospectus. As permitted by the rules and regulations of the Commission,
this Prospectus does not contain all of the information set forth in the
Registration Statement. For further information about SMT and the Securities
offered hereby, reference is made to the Registration Statement and to the
financial statements, exhibits and schedules filed therewith. The statements
contained in this Prospectus about the contents of any contract or other
document referred to are not necessarily complete, and in each instance
reference is made to the copy of such contract or other document filed as an
exhibit to the Registration Statement, each such statement being qualified in
all respects by such reference. Copies of each such document may be obtained
from the Commission at its principal office in Washington, D.C., upon payment of
the charges prescribed by the Commission. Electronic registration statements
made through the Electronic Data Gathering, Analysis, and Retrieval system are
publically available through the Commission's Web site (http://www.sec.gov).
INCORPORATION BY REFERENCE
The following documents filed by the Company with the Commission
pursuant to the Exchange Act are incorporated herein by reference: (a) Annual
Report on Form 10-K for the fiscal year ended December 31, 1995, as amended by
Amendment No. 1 thereto; (b) Quarterly Report on Form 10-Q for the fiscal
quarter ended March 31, 1996, as amended by Amendment No. 1 thereto; (c) Proxy
Statement dated March 28, 1996; and (d) The description of the Company's Common
Stock and Warrants contained in the registration statement on Form 8-A.
All documents subsequently filed by the Company pursuant to Section
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering shall be deemed to be incorporated by reference in this Prospectus and
to be a part hereof from the respective date of filing of each such document.
Any statement contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is, or is deemed to be, incorporated by
reference herein modifies or supersedes such statement. Any such statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Prospectus.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon written or oral request, a copy of any or all of
the documents incorporated by reference herein, other than certain exhibits to
such documents. Requests for such documents should be directed to David A. Zynn,
Chief Financial Officer, SMT Health Services Inc., 10521 Perry Highway, Wexford,
Pennsylvania 15090. The Company's telephone number is (412) 933-3300.
2
<PAGE>
RISK FACTORS RISK FACTORS
The purchase of the Securities being offered hereby involves a high
degree of risk and substantial dilution. Prospective investors should carefully
consider, among other matters, the following risks and other factors before
making a decision to purchase the Securities.
Significant Leverage and Repayment Obligations
The Company's business is highly capital intensive. The Company has
financed the acquisition of all of its Mobile Magnetic Resonance Imaging ("MRI")
equipment through capital leases and loans and as a result is highly leveraged.
At December 31, 1995, the Company's total liabilities were approximately $17.9
million and its capital was approximately $5.4 million. At March 31, 1996, the
Company's total liabilities were approximately $20.1 million and its capital was
approximately $5.9 million. The Company is therefore subject to the risks
associated with such substantial leverage, including the risk that cash flow may
not be adequate to make required payments on indebtedness. A decrease in
equipment utilization arising from, among other things, cancellation or
nonrenewal of contracts, equipment malfunctions, the inability to effect prompt
and timely repairs to equipment or a reduction in demand for the Company's
equipment or services could materially and adversely affect the Company's
ability to service its indebtedness.
The Company's monthly payments on its capital leases and other
long-term debt were approximately $550,000 as of March 31, 1996. Total payments
under the Company's capital lease obligations and other long-term debt may equal
or exceed minimum revenues receivable under the Company's service contracts if
such contracts are not renewed by healthcare providers, if receivables are not
collected by the Company on a timely basis or if the number of scans or other
services performed fails to meet expected levels. In such case, the Company
would be unable to meet its debt service obligations, and would be in default
under its various loan and lease agreements.
As of December 31, 1995, the Company's current assets were
approximately $5.6 million and its current liabilities were approximately $5.2
million, resulting in a working capital surplus of approximately $400,000. At
March 31, 1996, the Company's current assets were approximately $5.2 million,
and its current liabilities were approximately $5.8 million resulting in a
working capital deficit of $600,000. The change in working capital since year
end is primarily due to the acquisition of a mobile MRI provider during the
first fiscal quarter. Of such liabilities, approximately $4.4 million and $4.9
million represented the current portion of long-term debt and capital lease
obligations as of December 31, 1995 and March 31, 1996, respectively. There can
be no assurance that the Company's revenues will continue to be sufficient to
satisfy the increased lease payments or that such favorable terms will be
available in the future.
Equipment Maintenance, Service and Damage
All of the diagnostic imaging equipment utilized by the Company is
technologically sophisticated and complex, requires regular service and is
subject to unpredictable malfunctions and breakdowns. The Company contracts
with, and relies upon, the equipment manufacturer to provide maintenance
services on a prompt and timely basis. Because diagnostic imaging equipment is
technologically sophisticated, it is uncertain whether and how quickly others
could provide maintenance services if the equipment manufacturers were unable or
unwilling to do so. Consequently, the Company's business might be adversely
affected if the manufacturers stopped providing maintenance services.
Substantially all of the Company's tangible assets consist of
diagnostic imaging equipment, including primarily specially designed mobile MRI
units. Generally, a mobile unit is moved several times a week from one location
to another, and there is always a risk that a traffic accident or automotive
breakdown will occur while the equipment is in transit. Although the Company's
equipment is insured against the risks of damage in an accident, and the Company
is insured for business interruptions resulting from any damage to such
equipment for the period required to repair or replace the equipment, it may not
be possible to repair damaged equipment so that it will achieve its original
level of performance. Substitute or replacement equipment may be unavailable and
the quality of the potential replacement equipment unknown. In addition, there
is no assurance that the Company would receive sufficient insurance proceeds
following any damage to its equipment to fully compensate it for the losses
resulting from such damage or receive business interruption insurance proceeds
to compensate for lost business.
3
<PAGE>
Reimbursement of Health Care Costs
The Company receives payment directly from health care providers,
rather than from private insurers, other third party payors or governmental
entities, for its mobile MRI units. The Company's mobile service contracts with
its customers provide that the Company must be paid within 30 days of providing
its services and are not conditioned upon the receipt of payment by the
healthcare provider. Under current reimbursement regulations, the Company is
unable to bill the insurer or the patient directly for services provided for
hospital inpatients or outpatients. Payment to health care providers by third
party payors for the Company's diagnostic services depends substantially upon
such payors' reimbursement policies. Consequently, those policies have a direct
effect on health care providers' ability to pay for the Company's services and
the Company's level of charges. Mounting concerns about rising health care costs
may cause more restrictive reimbursement policies to be implemented in the
future. Restrictions on reimbursements to health care providers may affect such
providers' ability to pay for the services offered by the Company and could
indirectly adversely affect the Company's financial performance.
Other Reimbursement Matters
Many insurance companies, employers and other payors are increasing
their use of managed care plans such as health maintenance organizations
("HMOs") and preferred provider organizations ("PPOs") as a means of controlling
their healthcare costs. In addition to contracting with selected healthcare
providers to provide healthcare services, often at a discount or on a capitation
basis, such plans engage in strict utilization review activities to more closely
control the utilization of services by their subscribers. There can be no
assurance that the increased use of managed care plans in the Company's service
areas will not affect its level of charges or the demand for its services.
Numerous changes have been made in governmental and commercial
insurance programs in recent years in an effort to reduce the extent to which
these third-party payors absorb increases in medical costs. Some third-party
payors have also experienced difficulties in meeting their payment obligations
whether on a timely basis or otherwise. In addition, a number of bills proposing
to regulate, control or alter the methods of financing and delivering
healthcare, including proposals for a national health insurance program, have
been discussed and introduced in Congress and various state legislatures.
Further, Congress has proposed Medicare/Medicaid Reform which would limit
increases in governmental healthcare expenditures. The effect of any of these
proposals or changes by existing insurers in their reimbursement methodologies
on the healthcare industry and the Company cannot be determined at this time.
Availability of Equipment Financing; Timely Delivery of Equipment
Future acquisitions of equipment will be made pursuant to capital and
operating leases or purchase financing. Leases or loans for mobile MRI
equipment are generally in the original principal amount of approximately $1.8
million to $2.2 million per unit, depending upon the type, features and options
of the diagnostic imaging equipment leased. The Company's ability to expand is,
therefore, tied to the availability of lease or purchase financing. Although
the Company has in the past been able to procure lease and purchase financing,
there can be no assurance that lenders or equipment leasing companies will
continue to enter into leases or purchase financing with the Company.
The timely delivery of mobile MRI equipment is outside the control
of the Company and significant delays in delivery may materially and adversely
affect the Company. Such delays could arise from, among other things,
manufacturer and delivery delays.
4
<PAGE>
Government Regulation
General. The provision of diagnostic imaging services is subject to
a number of federal, state and local laws, regulations and rules, some of which
are very complex. Although the Company believes that it is currently in
compliance with applicable laws, regulations and rules, some of such laws are
broadly written and subject to little or no interpretation by courts or
administrative authorities. Hence, there can be no assurance that a third party
or governmental agency will not contend that certain aspects of the Company's
operations or procedures are not in compliance with such laws, regulations or
rules or that state agencies or courts would interpret such laws, regulations
and rules in the Company's favor. The sanctions for failure to comply with such
laws, regulations or rules could be denial of the right to conduct business,
significant fines and/or criminal penalties. Additionally, an increase in the
complexity or substantive requirements of such laws, regulations or rules could
adversely affect the Company's business.
Certificate of Need. In addition, several states in which the Company
operates have certificate of need ("CON") laws and regulations that control and
regulate the establishment of healthcare facilities and services and the
acquisition and operation by hospitals and other providers of major equipment
such as MRI units and other diagnostic imaging equipment. In several states in
which the Company operates, a hospital or the Company may need a CON before the
Company can provide its diagnostic imaging services. CON regulations could
inhibit the expansion of the Company's business.
Practice of Medicine. The establishment, marketing and operation of
the diagnostic imaging units are subject to laws prohibiting the practice of
medicine by non-physicians. The Company's employees provide only the technical
services relating to the diagnostic procedures (under the supervision of
licensed physicians) and the related non-medical administrative support
services. Professional medical services, such as the reading of the diagnostic
imaging studies and related diagnosis, are separately provided by licensed
physicians. The Company does not employ any physicians to provide medical
services. There can be no assurance, however, that state authorities or courts
will not determine that the Company's services and/or relationships with
providers constitute the unauthorized practice of medicine by the Company.
Fraud and Abuse Laws. The Social Security Act and certain provisions
of state law provide civil and criminal penalties for persons who knowingly and
willfully solicit, pay, offer or receive any remuneration, directly or
indirectly, as an inducement to make a referral of a patient for services or
items for which payment may be made under the Medicare or Medicaid programs.
Often termed "fraud and abuse" or "anti-kickback" laws, the provisions have been
broadly interpreted by the courts.
The Office of Inspector General of the Department of Health and
Human Services ("HHS") has issued regulations specifying certain business
arrangements and payment practices involving providers or other entities, such
as the Company, which will not be considered prohibited activities. Commonly
termed "safe harbor regulations," the regulations set forth certain standards
which, if satisfied, will ensure that the arrangement will not be subject to
criminal prosecution or civil sanctions under the fraud and abuse laws. Failure
to satisfy the safe harbors in and of itself does not render an arrangement
illegal. The Company believes it is in compliance with the safe harbor
regulations applicable to its current operations.
One principal focus of the fraud and abuse laws has been on
arrangements in which profit distributions are made by a partnership or other
business venture for health-related items or services to investors who make or
are otherwise in a position to influence referrals of Medicare or Medicaid
patients to the venture. Where such arrangements exist, a question is raised as
to whether the profit distributions are illegal payments in exchange for
referrals. Certain safe harbors set forth criteria which, if met, will insure
that investors in business ventures for health-related items or services will
not be subject to scrutiny under the fraud and abuse laws.
One safe harbor protects profit distributions to investors made by
publicly traded companies with tangible assets of more than $50 million. At
present, the Company does not satisfy the asset threshold for protection under
this safe harbor.
5
<PAGE>
Another safe harbor covers investment interests in small entities.
The conditions for compliance with this safe harbor include, among other things,
requirements that no more than 40% of the investment interests of each class of
investments in the entity may be held by persons who are in a position to make
or influence referrals (including hospitals and physicians), furnish items or
services to the entity or otherwise generate business for the entity, so-called
"tainted investors," and that no more than 40% of the entity's gross revenues
may come from referrals, items or services furnished or business otherwise
generated by "tainted investors." Unless a large percentage of the Company's
Common Stock or Warrants are held by "tainted investors," it would appear that
investments in the Company will fall within the safe harbor for investment
interests.
None of the Company's mobile MRI activities are carried out through
partnerships or other ventures with hospitals, physicians or other third
parties.
The laws involving fraud and abuse and the safe harbor regulations are
currently in a rapid state of development and it is difficult to provide a clear
analysis of the risks in this area. There can be no assurance that enforcement
agencies or courts will determine that any existing arrangements comply with all
applicable laws and regulations.
Other Patient Referral Restrictions. Additionally, Pennsylvania, as
well as other states in which the Company operates, prohibits the referral of
Medicaid patients for services or items by a provider in which the referring
physician has an ownership interest. Certain states do not restrict patient
referrals but do require the disclosure to a patient by the referring physician
of a financial interest in a facility or vendor to which the patient is being
referred for services or items.
Stark II. The Omnibus Budget Reconciliation Act of 1993 enacted new
federal anti-referral legislation, more commonly known as "Stark II" after its
prime sponsor, Rep. Fortney "Pete" Stark (D. Calif.). Effective January 1, 1995,
Stark II bans referrals by physicians of Medicare and Medicaid patients to
entities for certain designated health services, including MRI services, if a
physician or immediate family member has a prohibited financial relationship
with the entity providing the service. A financial relationship is generally
defined as an ownership or investment interest in or compensation arrangement
with the entity, subject to certain exceptions. Penalties include nonpayment for
services rendered pursuant to a prohibited referral, civil money penalties and
fines and possible exclusion from the Medicare and Medicaid programs. The
Company believes it is currently in compliance with the requirements of Stark
II. However, there can be no assurance that enforcement agencies or courts will
determine that existing arrangements comply with all applicable laws and
regulations.
Need for Additional Financing
The Company expects that its current cash balances, future cash flows
anticipated to be generated from operations and currently available equipment
financing arrangements will be sufficient to fund the Company's operations
through at least fiscal year 1997. This estimate is based on certain
assumptions, including the maintenance of expenses and cash flows from
operations at historical levels. There can be no assurance that these
assumptions will be realized or that a sufficient level of equipment utilization
will be attained to fund operations after the stated period. The failure to
achieve these assumptions may decrease the period of time for which the Company
estimates that these funds will be sufficient.
Reliance on Key Personnel
The Company's success depends in large part upon a number of key
management personnel and technical employees. The loss of the services of one or
more of its management personnel, in particular Jeff D. Bergman, Daniel Dickman,
David Zynn and David Spindler, could have a material adverse effect on the
Company. The Company has key man life insurance covering Messrs. Bergman,
Dickman and Spindler.
The ability of the Company to attract and retain qualified
technicians to operate the diagnostic imaging equipment is crucial to the
operations of the Company. Such technicians are in short supply and are
typically attracted to nonmobile facilities which provide predictable locations
and work schedules. In contrast, mobile facilities provide
6
<PAGE>
very unpredictable work schedules and constantly changing locations which may
not be attractive to a large portion of technicians. Therefore, the Company may
experience some difficulty finding qualified technicians for its mobile MRI
units. The Company believes its future success will depend in part on its
ability to attract and retain highly skilled employees. To date, the Company has
been able to attract sufficient technicians, although there can be no assurance
that this will continue in the future.
Technological Change and Obsolescence
The Company's services require the use of state-of-the-art medical
diagnostic equipment that has been characterized by rapid technological
advances. Although the Company believes that the equipment it provides can be
upgraded to maintain its state-of-the-art character, the development of new
technologies or refinements of existing ones might make the Company's existing
equipment technologically or economically obsolete, or cause a reduction in the
value of, or reduce the need for, the Company's equipment. Diagnostic imaging
equipment is currently manufactured by numerous companies. Competition among
manufacturers for a greater share of the diagnostic imaging equipment market may
have the effect of generating greater technological advances in the capacity of
this new equipment. Consequently, the obsolescence of the Company's equipment
may be accelerated. Although the Company is aware of no substantial
technological change, should such change occur there can be no assurance that
the Company will be able to acquire the new or improved equipment which may be
required to service its customers.
Other Requirements Concerning Licensing, Permits and Approvals
Most states do not currently license MRI providers such as the
Company. Hospitals with which the Company has contracted are subject to a
variety of regulations and standards of state licensing and other authorities
and accrediting bodies such as the Joint Commission for the Accreditation of
Healthcare Organizations ("JCAHO"). As an outside vendor, the Company may be
required to comply with such regulations and standards to enable the hospitals
with which it has contracted to maintain their permits, approvals and
accreditations.
There can be no assurance that future changes in the laws and
regulations relating to the delivery of healthcare items and services may
require the Company or any venture involving the Company to obtain and maintain
certain governmental approvals for continued operations. It is not possible to
predict the effect of such changes in the law on the Company at this time.
For the most part, the Company's employees need not have special
licenses. Drivers of trucks must have certain special driving licenses. MRI
technicians are not required to have licenses in any of the states in which the
Company does business. However, many states are holding discussions to require
such licensing and to require continuing education. The Company believes that
any such licensing requirement would not have any adverse impact on the Company.
Competition
The healthcare industry in general, and the market for diagnostic
imaging services in particular, is highly competitive. Certain competitors
operate fixed-site centers and mobile units in the Company's current service
area. Some competitors may have financial resources substantially greater than
those of the Company which may give them advantages in negotiating equipment
acquisitions and responding quickly to new demand or new technology. In
addition, hospitals, private clinics and radiology practices in the Company's
service area have in-house equipment which competes with the Company. MRI also
competes with less expensive diagnostic imaging devices and procedures which may
provide similar information to the physician. Existing healthcare providers who
are currently customers of the Company may purchase diagnostic imaging equipment
if the cost of such equipment decreases or if their volume of patients increases
to the point where it becomes cost-effective to own and operate their own
equipment.
Insurance
The Company carries workers' compensation insurance, comprehensive
and general liability insurance, business interruption, fire and allied perils
coverage in amounts deemed adequate by the Company. The Company
7
<PAGE>
requires that its healthcare customers maintain professional liability insurance
and the Company maintains its own professional liability policy. There can be no
assurance that claims will not exceed the amounts of insurance coverage, that
the cost for such coverage will not increase to the extent that the Company will
be forced to self-insure a substantial portion of this risk, or that such
coverage will not be reduced or become unavailable.
Control of Company
The Company's officers and directors as a group beneficially own
approximately 33.5% of the Company's Common Stock and are able to exert
considerable influence over the affairs and policies of the Company.
Dividends
The Company has not paid, and does not anticipate paying in the
foreseeable future, cash dividends on its Common Stock.
On July 10, 1995, the Company paid a 5% stock dividend to all holders
of record of its Common Stock as of June 30, 1995.
Current Prospectus and State Registration Required to Exercise Warrants,
Possible Redemption of Warrants
Holders of the Warrants will be able to exercise them only if a
current prospectus relating to the Common Stock underlying the Warrants is then
in effect and only if such Common Stock is qualified for sale or exempt from
qualification under the applicable securities laws of the states in which the
various holders of Warrants reside. Although the Company will use its best
efforts to maintain the effectiveness of a current prospectus covering the
Common Stock underlying the Warrants, there can be no assurance that the Company
will be able to do so. The Company will be unable to issue Common Stock to those
persons desiring to exercise their warrants if a current prospectus covering the
Common Stock issuable upon the exercise of the Warrants is not kept effective or
if such Common Stock is not qualified nor exempt from qualification in the
states in which the holders of the Warrants reside. In November 1995, the
Company's securities began to trade on the Nasdaq National Market, and
accordingly there may be exemptions available in substantially all of the
states. The Warrants (other than the 126,000 Warrants held by the Stratton
Transferees upon exercise of the Option) are subject to redemption by the
Company at any time at $.05 per warrant on 30 days' prior written notice if the
closing bid price of the Common Stock shall have averaged in excess of $9.53
per share (subject to adjustment) for 20 consecutive business days ending
within 5 days of the date on which notice of redemption is given. If the
Warrants are redeemed, the warrant holders will lose their right to exercise
the Warrants except during such 30-day redemption period. Redemption of the
Warrants could force the holders to exercise the Warrants at a time when it may
be disadvantageous for the holders to do so or to sell the Warrants at the then
market value of the Warrants at the time of redemption.
Shares Eligible for Future Sale
As of the date hereof, there were 3,087,225 shares of Common Stock
issued and outstanding, excluding 1,793,348 shares issuable by the Company upon
exercise of the Warrants, 126,000 shares of Common Stock issuable to the
Stratton Transferees, upon exercise of an option, 100,000 shares issuable to
Commonwealth Associates, the Company's former investment banking firm, upon
exercise of 100,000 warrants (the "Commonwealth Warrants") and 949,100 shares
issuable to certain officers and directors upon exercise of options and rights
held by them. Of such 3,087,225 shares of Common Stock, 1,449,000 shares of
Common Stock were sold in the IPO, 693,000 shares were sold by certain selling
stockholders pursuant to registration statements under the Securities Act of
1933, as amended (the "Securities Act") and 438,825 shares were issued pursuant
to the exercise of options under registration statements under the Securities
Act. The remaining 506,400 shares of Common Stock are "restricted securities"
(as that term is defined under Rule 144 promulgated under the Securities Act)
held by four (4) persons. The Company believes that all but 120,000 of such
shares have been held for at least two years and may be sold in accordance with
Rule 144. The sale, or availability for sale, of substantial amounts of Common
Stock in the public market, or any additional offering of Common Stock, could
adversely affect the prevailing market price of
8
<PAGE>
the Common Stock and could impair the Company's ability to raise additional
capital through the sale of its equity securities.
Sale of Discontinued Operations
As previously disclosed in the Company's public filings, the Company
implemented a plan which it believed would lead to the divestiture of its
outpatient healthcare centers during 1994. On October 31, 1994, the Company
sold substantially all of the assets of its radiation therapy center located in
Auburn, Washington, for a total sale price of approximately $1.3 million. The
sale of the center did not result in a gain or loss and resulted in cash
proceeds to the Company of $400,000. The Company remains obligated on
approximately $400,000 of capital leases as of March 31, 1996. The buyer has
agreed to use its best efforts to have the Company released from these leases
and has secured its obligations to the Company to perform these leases through a
pledge of certain assets in favor of the Company.
On June 30, 1995, the Company completed the sale of substantially
all of the assets of its remaining outpatient healthcare center, Airport
Regional Imaging Center, located in Coraopolis, Pennsylvania, as well as its
sixty percent ownership and general partner interests in all of its cardiac care
centers to Cardiac Fitness Inc., or an affiliate thereof, for a total sale price
of approximately $600,000, including cash and net trade receivables of
approximately $500,000 and a note of $100,000. Although the buyer assumed all
future operating liabilities of the healthcare center, the Company remains
obligated on approximately $700,000 of capital leases as of March 31, 1996. The
buyer has agreed to use its best efforts to have the Company released from these
leases and has secured its obligations to the Company to perform these leases
through a pledge of stock and certain assets in favor of the Company.
------------------------
The sale of the healthcare center, which had previously been treated
as a discontinued operation, did not result in a gain or loss. The sale of the
sixty-percent ownership and general partnership interests in the cardiac care
centers which were treated as continuing operations, resulted in an approximate
$50,000 pre-tax gain which was recorded in the second quarter of 1995.
------------------------
Although it will have no legal obligation to do so, any underwriter
participating in this offering may, from time to time, act as a market maker or
otherwise effect transactions in the Company's securities. Such underwriter, or
other underwriters participating in the offering, if any, may be dominating
influences in the market for the Warrants. The price and liquidity of the
Warrants may be affected by the degree, if any, of such underwriter
participation in the market. Such activities, if commenced, may be discontinued
at any time or from time to time and may require the Company to establish new
market makers.
------------------------
THE COMPANY
The Company is primarily engaged in the business of operating mobile
MRI units. MRI involves the use of high strength magnetic fields and radio
waves to produce cross-sectional images of the anatomy. MRI facilitates the
diagnosis in the early stages of disease without the need for exploratory
surgery or other invasive procedures. MRI has become a preferred diagnostic
tool of the medical profession because it is non-invasive and its images are
generally better defined and more precise than those produced by other
diagnostic imaging tests, without the use of harmful ionizing radiation, such as
that produced by computed axial tomography ("CAT") scans and standard x-rays.
The Company provides mobile MRI services to healthcare providers,
which consist primarily of small and medium size hospitals. Including a new MRI
unit acquired in February 1996 and the purchase of two new units from another
mobile provider in March 1996, the Company currently operates fourteen mobile
MRI units which service healthcare providers located in Pennsylvania, North
Carolina, West Virginia, Ohio, Virginia and Kentucky. The MRI equipment is
transported in specially designed vans that are driven to the healthcare
provider's facility where the imaging occurs. The healthcare provider pays the
Company on a per scan basis for the use of the equipment. The healthcare
providers utilizing the Company's services have a need for MRI services, but do
not own their own
9
<PAGE>
equipment due to insufficient patient volume to justify a full-time fixed MRI
unit, the high cost of owning and operating such equipment, the lack of
expertise in this highly specialized field or due to regulatory constraints.
The Company was formed in November 1991 to merge with Shared Medical
Technologies, Inc., a Pennsylvania corporation incorporated in 1987 ("Old SMT")
and Shared MRI-4, Inc., a Pennsylvania corporation ("MRI-4"), and to acquire
substantially all of the assets and assume substantially all of the liabilities
of Shared MRI-1, L.P., a Pennsylvania limited partnership ("MRI-1") and Shared
MRI-3, L.P., a Pennsylvania limited partnership ("MRI-3") (Old SMT, MRI-4, MRI-1
and MRI-3 are collectively referred to as the "SMT Group"), each of which leased
one, and in the case of Old SMT, two, mobile MRI units (the "Consolidation").
As of November 1991, all of the four entities comprising the SMT Group were
owned or controlled by Jeff D. Bergman, Daniel Dickman and Mark A. DeSimone,
who (along with Mr. DeSimone's wife) are holders of 564,575 shares, or
approximately 18%, of the Company's outstanding Common Stock. Messrs. Bergman,
Dickman and DeSimone in the aggregate are beneficial owners of an additional
538,500 shares through rights to acquire the Company's Common Stock. The assets
of MRI-1 and MRI-3 were acquired by the Company in exchange for an aggregate of
$1,300,000 in notes (the "LP Notes"), the assumption of approximately $2,600,000
of liabilities of the partnerships (primarily relating to the capital leases for
the MRI equipment) and 99,950 Warrants. In March 1992, the LP Notes were
redeemed, utilizing a portion of the net proceeds of the IPO.
In March 1992, the Company effectuated an underwritten initial public
offering (the "IPO") of Units, each Unit consisting of one share of Common Stock
and one Warrant to purchase a share of Common Stock for $7.00 (subsequently
adjusted to $6.67 as a result of a stock dividend). The Units traded on Nasdaq
from March 4, 1992, until October 15, 1992. On October 16, 1992 (the
"Separation Date"), the Common Stock and Warrants began to trade separately on
Nasdaq under the symbols "SHED" and "SHEDW," respectively, and the Units were
delisted from trading on Nasdaq.
During November 1995, the Company's Common Stock and warrants began to
trade on the Nasdaq National Market under the symbols SHED and SHEDW,
respectively.
The Company's executive offices are located at 10521 Perry Highway,
Wexford, Pennsylvania 15090, and its telephone number is (412) 933-3300. Unless
the context requires otherwise, with respect to events occurring prior to the
Consolidation, the "Company" may refer to one or more of the entities comprising
the SMT Group.
USE OF PROCEEDS
The Company will not receive any of the proceeds from the sale of the
Warrants offered hereby by the Selling Stockholders.
SELLING STOCKHOLDERS
The 126,000 Warrants offered by the Stratton Transferees are issuable
upon exercise of the Option which was issued in the IPO to Stratton as
underwriter of the IPO. The Option is exercisable for 120,000 Units, each Unit
consisting of 1.05 shares of Common Stock and one Warrant to purchase 1.05
shares of Common Stock. The 2,100 Warrants that may be offered hereby by Mr.
Bergman were acquired in open market transactions.
For a description of the manner in which the Warrants offered by the
L.P. Holders were acquired by the Selling Stockholders, see "The Company."
See the disclosure following this table for information regarding any
position, office or material relationship that each of the Selling Stockholders
has had with the Company during the past three years.
The following table sets forth information with respect to the
beneficial ownership of Warrants by the Selling Stockholders as of the close of
business on June 11, 1996, all of which may be offered from time to time
10
<PAGE>
hereby. As of the date of this Prospectus, assuming the sale by each of the
Selling Stockholders of all of the Warrants listed below, the Company believes
that none of such Selling Stockholders would beneficially own any Warrants.
<TABLE>
<CAPTION>
Beneficial Ownership
----------------------------------------
Name of Selling Stockholder Number of Warrants Percentage of Class
- ----------------------------------------------- -------------------- -------------------
<S> <C> <C>
Jeff D. Bergman 2,000 *
c/o SMT Health Services Inc.
10521 Perry Highway
Wexford, Pennsylvania 15090
Daniel Porush 30,000 1.7
c/o Stratton Oakmont Inc.
1978 Marcus Avenue, Suite 120
Lake Success, New York 11042
Kenneth Greene 24,000 1.3
c/o Stratton Oakmont Inc.
1978 Marcus Avenue, Suite 120
Lake Success, New York 11042
Jordan Belfort 66,000 3.7
5 Pin Oak Court
Old Brookville, New York 11545
L.P. Holders:
Joseph A. Hardy, Jr. 12,000 *
111 Oakwood Road
McMurray, Pennsylvania 15317
James M. Wills, MD 6,000 *
211 Fairview Avenue
Beckley, West Virginia 25801
Dr. Henry Higman 3,000 *
176 Topsfield Road
Pittsburgh, Pennsylvania 15241
Frank A. Getting 3,000 *
U.S. Cleaning Custodian FBO IRA
R.D. #1 Box 564
Boyerstown, Pennsylvania 19512
Dominic W. Dileo, M.D. 3,000 *
Spring Creek Cardio-Medical Assoc. Inc.
Profit Sharing Plan & Trust Agreement
6 Spring Creek Lane
Uniontown, Pennsylvania 15401
Richard M. Thompson, M.D. 3,000 *
22 Tanager Place
Beckley, West Virginia 25801
Jane B. Lewis 3,000 *
1320 Governor's Drive
Corsicana, Texas 75110
Waldo Porter 3,000 *
1150 Fox Chapel Road
Pittsburgh, Pennsylvania 15238
George A. Hackett 3,000 *
1585 Oakleaf Lane
Pittsburgh, Pennsylvania 15237
</TABLE>
11
<PAGE>
<TABLE>
<CAPTION>
Beneficial Ownership
----------------------------------------
Name of Selling Stockholder Number of Warrants Percentage of Class
- ----------------------------------------------- -------------------- -------------------
<S> <C> <C>
Mrs. H.F. Contractor 2,350 *
2301 Colony Court
Pittsburgh, Pennsylvania 15237
Kenneth J. Yablonski 2,350 *
28 Woodside Drive
Washington, Pennsylvania 15301
Jay B. Kovan/Juliet B. Sutherlan 2,350 *
488 Ridgewood Road
Maplewood, New Jersey 07040
Gordon E. Banks, M.D. 1,500 *
Falk Clinic Neurology
3601 Fifth Avenue
Pittsburgh, Pennsylvania 15241
Bujaky, Koeler, Libson & Assoc. 1,500 *
206 Siebert Road
Pittsburgh, Pennsylvania 15237
Ralph Arnold 1,500 *
9147 Lancelot Drive
Pittsburgh, Pennsylvania 15237
Helen E. Simpson 1,500 *
3530 Simen Avenue
Pittsburgh, Pennsylvania 15212
Raymond Lindsay Lilly Jr., M.D. 1,500 *
Route 66, Box 99-C
Daniels, West Virginia 25832
Robert S. Koehler 1,500 *
412 Santa Rosa Lane
Pittsburgh, Pennsylvania 15237
Geoffrey G. Wright 1,500 *
138 Vernon Drive
Pittsburgh, Pennsylvania 15228
Frank P. Wolber 1,500 *
4517 W. Brightview Avenue
Pittsburgh, Pennsylvania 15227
D. Leet Shields 1,500 *
436 Beaver Road
Pittsburgh, Pennsylvania 15143
Robert C. Farmer, M.D. 1,175 *
P.O. Box 882
Connellsville, Pennsylvania 15425
Peter Gabriel, M.D. 1,175 *
8 Adams Lane
Uniontown, Pennsylvania 15401
Richard A. Cook 1,175 *
132 Southwood Drive
Uniontown, Pennsylvania 15401
Oscar M. Reinmuth, M.D. 1,175 *
6104 Kentucky Avenue
Pittsburgh, Pennsylvania 15206
Ceasar N. Noche, M.D. 1,175 *
136 Belmont Circle
Uniontown, Pennsylvania 15401
Ernst Braun, M.D. 1,175 *
30 Mont View Street
Uniontown, Pennsylvania 15401
Thomas M. Persico, D.M.D. 1,175 *
6th Street & Donner Avenue
Monessen, Pennsylvania 15062
</TABLE>
12
<PAGE>
<TABLE>
<CAPTION>
Beneficial Ownership
----------------------------------------
Name of Selling Stockholder Number of Warrants Percentage of Class
- ----------------------------------------------- -------------------- -------------------
<S> <C> <C>
Thomas M. Persico, D.M.D. (Trust) 1,175 *
Guarantee & Trust Co.
TTEE FBO Thomas M. Persico
c/o Parker/Hunter
600 Grant Street
Pittsburgh, Pennsylvania 15219
Robert R. Buchman, M.D. 1,175 *
2878 Fernwald Road
Pittsburgh, Pennsylvania 15217
Mallard T. George D.D.S. 1,175 *
80 Belmont Circle
Uniontown, Pennsylvania 15401
Walter E. Smith, M.D. 1,175 *
Suite 200, 6393 Penn Avenue
Pittsburgh, Pennsylvania 15206
Charles P. Yezbak Jr., D.D.S. 1,175 *
56 Stockton Avenue
Uniontown, Pennsylvania 15401
Ms. Paula Ducoeur 1,175 *
901 5th Street
Charleroi, Pennsylvania 15022
Peter P. Tanzer, M.D. 1,175 *
1155 Shady Avenue
Pittsburgh, Pennsylvania 15232
K.Y. Ou/C.D. Young (MD's) 1,175 *
7405 Irvine Street
Pittsburgh, Pennsylvania 15218
</TABLE>
13
<PAGE>
<TABLE>
<CAPTION>
Beneficial Ownership
----------------------------------------
Name of Selling Stockholder Number of Warrants Percentage of Class
- ----------------------------------------------- -------------------- -------------------
<S> <C> <C>
All Other L.P. Holders (18 persons) 15,275 *
</TABLE>
____________________
*Less than 1%.
The following sets forth information regarding any position, office or
material relationship that each of the Selling Stockholders has had with the
Company during the past three years.
Mr. Bergman (Chairman, Chief Executive Officer and President of the
Company) owns a one-third equity interest in a partnership, Shared Mobile
Enterprises ("SME"), which leased and subleased to the Company certain tractors
for the transportation of mobile MRI units. Mr. Dickman (Chief Operating
Officer and a director of the Company) also owns a one-third interest in SME
while the remaining one-third interest is owned by L.M. Paul. Ms. Paul is the
spouse of Mark A. DeSimone, a former director and consultant to the Company.
SME received a lease payment of approximately $2,500 per month plus
reimbursement of expenses from the Company for each tractor. At December 31,
1993, 1994 and as of June 30, 1995, the Company was leasing ten, ten and eleven
tractors, respectively, from SME. During 1993, 1994 and 1995, lease payments to
SME were approximately $258,000, $257,000 and $180,000, respectively. The
Company believes that the terms of its leases with SME were as favorable, in all
material respects, as might have been obtained from an unaffiliated third party.
Effective July 1, 1995, SME released the Company from its obligations under
ten long term subleases in exchange for the issuance to SME of 120,000
unregistered shares of Common Stock valued at $3 per share, the weighted average
closing price for the stock for the prior thirty trading days. The Company
received an opinion from an independent financial advisor that the transaction
was fair to the Company and its stockholders. At the same time, with the
concurrence of the third party leasing company, the Company assumed SME's
obligations under its original lease and modified that lease by (1) extending
the lease term by one additional year and (2) adding one additional truck cab to
the schedule of leased property with a corresponding increase in base rental
payments. The $360,000 value of the shares represents the present value of the
excess of the sublease payments over the original lease payments. The Company
has capitalized the $360,000 and is amortizing this prepaid rent over a period
which approximates the lease term.
In March 1995, the Company entered into a five-year employment agreement
with each of Jeff D. Bergman and Daniel Dickman, pursuant to which Mr. Bergman
agreed to serve as the Chairman of the Board, President and Chief Executive
Officer of the Company and Mr. Dickman as the Executive Vice President and Chief
Operating Officer, each at an annual base salary of not less than $180,000. The
employment agreements provide that if the
14
<PAGE>
employee is terminated other than for "cause" or if the employee terminates for
"good reason" (including a change in control event), the employee shall be
entitled to a continuation of full salary and bonus compensation for a period
equal to the remainder of the term. The agreements further provide for a lump
sum payment of two and one-half times salary, bonus and certain other amounts
and continuation of certain benefits in the event that the employee is
terminated in connection with a change in control of the Company. Both contracts
provide for annual profit sharing with other executive level employees of a
bonus pool consisting of 15% of the Company's consolidated income before taxes,
determined in accordance with generally accepted accounting principles for
financial reporting purposes. Each of these Executive Officers received
approximately $74,000 pursuant to the bonus pool for services rendered in 1994.
Stratton was the underwriter of the Company's initial public
offering. In connection with the initial public offering, Stratton received
underwriting commission of $690,000, an expense allowance of $207,000, and
certain indemnifications.
As additional compensation in connection with the initial public
offering, the Company granted to Stratton the Option which covers 120,000 units,
each unit consisting of 1.05 shares of Common Stock and one Warrant to purchase
1.05 shares of Common Stock. The Option is exercisable until March 4, 1997 and
entitles Stratton to purchase each unit at an exercise price equal to $5.94,
subject to adjustment in certain events. Stratton subsequently transferred the
Option to the Stratton Transferees, who are selling stockholders.
On August 9, 1995, the Company adopted the 1995 Director Warrant Plan
(the "Plan") pursuant to which eligible directors received unregistered warrants
to purchase Common Stock. The Plan allows for issuance of warrants to purchase
up to 700,000 shares of Common Stock.
On August 9, 1995, warrants to purchase up to 500,000 shares of
Common Stock at an initial exercise price of $3.875, the closing price of the
Company's stock on the date of issue, were issued to five directors including
Mr. Bergman. Separately, unregistered warrants to purchase 114,500 shares of
Common Stock at an initial exercise price of $4.01 were also issued to an
outside director, who is also a consultant to the Company, who was ineligible to
participate in the Plan.
PLAN OF DISTRIBUTION PLAN OF DISTRIBUTION
The Company has been advised that the Warrants offered by the Selling
Stockholders may from time to time be offered and sold by the Selling
Stockholders to or through underwriters, through one or more agents or dealers
or directly to purchasers. The distribution of the Warrants may be effected from
time to time in one or more transactions at a fixed price or prices, which may
be changed, at market prices prevailing at the time of sale, at prices related
to such prevailing market prices or at negotiated prices. The Company has been
further advised that offers to purchase Warrants may be solicited directly by
the Selling Stockholders or by agents designated by the Selling Stockholders
from time to time.
If sold through agents, the Warrants may be sold from time to time
by means of (i) ordinary brokers' transactions, (ii) block transactions (which
may involve crosses) in accordance with the rules of any stock
15
<PAGE>
exchange or trading system on which the Warrants are admitted for trading
privileges (the "Markets"), in which such an agent may attempt to sell the
Warrants as agent but may position and resell all or a portion of the blocks as
principal, (iii) "fixed price offerings" off the Markets (as described below) or
(iv) any combination of such methods of sale, in each case at market prices
prevailing at the time of sale in the case of transactions on the Markets and at
prices related to prevailing market prices or negotiated prices in the case of
transactions off the Markets. In connection therewith, distributors' or sellers'
commissions may be paid or allowed. If an agent purchases Warrants as principal,
such stock may be resold by any of the methods of sale described above.
From time to time an agent may conduct a "fixed price offering" of
Warrants off the Markets. In such case, such agent would purchase a block of
Warrants from the Selling Stockholders and would form a group of selected
dealers to participate in the resale of the shares.
If a dealer is utilized in the sale of Warrants, the Selling
Stockholders may sell such Warrants to the dealer as principal. The dealer may
then resell such Warrants to the public at varying prices determined by such
dealer at the time of resale.
In connection with the sale of Warrants, underwriters or agents may
receive compensation from the Selling Stockholders or from purchasers of
Warrants for whom they may act as agents in the form of discounts, concessions
or commissions. Underwriters or agents may sell Warrants to or through dealers,
and such dealers may receive compensation in the form of discounts, concessions
or commission from the underwriters or agents and/or commissions from the
purchasers for whom they may act as agents. Underwriters, agents and dealers
that participate in the distribution of Warrants may be deemed to be
underwriters, and any discounts or commissions received by them from the Selling
Stockholders and any profit on the resale of Warrants by them may be deemed to
be underwriting discounts and commissions, under the Securities Act of 1933, as
amended ("Securities Act").
Under agreements which may be entered into by the Company and the
Selling Stockholders, underwriters and agents who participate in the
distribution of Warrants may be entitled to indemnification by the Selling
Stockholders and the Company against certain civil liabilities, including
liabilities under the federal securities laws, or to contribution by the Selling
Stockholders and the Company to payments which such underwriters or agents may
be required to make in respect thereof. Underwriters, agents and dealers may
engage in transactions with or perform services for the Selling Stockholders
and/or the Company in the ordinary course of business.
EXPERTS
The financial statements and the related financial statement schedules
incorporated in this Prospectus by reference from the Company's Annual Report on
Form 10-K, as amended by Amendment No. 1 thereto, as of and for the years ended
December 31, 1995 and December 31, 1994, have been audited by KPMG Peat Marwick
LLP; and for the year ended December 31, 1993 have been audited by Deloitte &
Touche LLP, independent auditors, as stated in their respective reports which
are incorporated herein by reference, and have been so incorporated in reliance
upon the reports of such firms given upon their authority as experts in
accounting and auditing.
Certain legal matters with respect to the Warrants offered hereby have
been passed upon for the Company by Buchanan Ingersoll Professional Corporation.
16
<PAGE>
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
+ +
+ Information contained herein is subject to completion or amendment. A +
+ registration statement relating to these securities has been filed with +
+ the Securities and Exchange Commission. These securities may not be sold +
+ nor may offers to buy be accepted prior to the time the registration +
+ statement becomes effective. This prospectus shall not constitute an offer +
+ to sell or the solicitation of an offer to buy nor shall there be any sale +
+ of these securities in any State in which such offer, solicitation or sale +
+ would be unlawful prior to registration or qualification under the +
+ securities laws of any such State. +
+ +
++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Subject to Completion, dated June 14, 1996
PROSPECTUS
SMT HEALTH SERVICES INC.
100,000 Warrants
This Prospectus relates to an aggregate offering of up to 50,000
warrants (the "Commonwealth Warrants") to purchase the common stock, par value
$.01 per share (the "Common Stock"), of SMT Health Services Inc., a Delaware
corporation ("SMT" or the "Company") by each of Commonwealth Associates, the
Company's former investment banking firm, and Andres V. Bello, a Managing
Director of Commonwealth Associates. Commonwealth Associates and Mr. Bello each
received such Commonwealth Warrants from the Company in connection with the
engagement of Commonwealth Associates as the Company's investment banker and
financial advisor. Each Commonwealth Warrant entitles the holder to purchase one
share of the Company's Common Stock, par value $.01, at an initial exercise
price of $4.47, subject to adjustment in certain events, at any time until 5:00
p.m. Eastern Time on October 9, 2000. There are certain restrictions on transfer
of the Commonwealth Warrants. See "Description of Securities."
There is no market for the Commonwealth Warrants and none is expected
to develop. The Company has outstanding and listed for trading on the Nasdaq
National Market under the symbol SHEDW one class of warrants (the "Public
Warrants"). The Commonwealth Warrants are not equivalent to the Public Warrants.
The closing sale price of the Public Warrants, as quoted in the Nasdaq National
Market, was $3.375 on June 11, 1996.
The Company's Common Stock also is traded on the Nasdaq National
Market, under the symbol SHED. The closing sale price, as quoted in the Nasdaq
National Market for the Common Stock was $10.125 per share on June 11, 1996.
The Company will not receive any of the proceeds from the sale of the
Commonwealth Warrants by the Selling Stockholders. Expenses of this offering,
estimated at $40,000, are payable by the Company. See "Plan of Distribution."
Reference is hereby made to and prospective investors should consider
the concurrent offering of the Company's Common Stock through which
substantially all of the Common Stock beneficially owned by the Company's
directors and executive officers is registered for sale. Such offering is being
made through a separate prospectus which is available from the Company on
request. See "The Company."
The Commonwealth Warrants offered hereby are speculative and involve a
substantial degree of risk. Prospective investors should carefully consider the
factors set forth under "Risk Factors."
NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THIS OFFERING TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS PROSPECTUS AND,
IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS
HAVING BEEN AUTHORIZED BY THE COMPANY, THE SELLING STOCKHOLDERS OR ANY OTHER
PERSON. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION
OF AN OFFER TO PURCHASE ANY WARRANTS OTHER THAN THOSE TO WHICH IT RELATES, NOR
DOES IT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO PURCHASE BY
ANY PERSON IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL FOR SUCH PERSON TO MAKE
SUCH AN OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY
SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT
THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE
DATE HEREOF.
--------------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE
ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS
A CRIMINAL OFFENSE.
--------------------------------
The date of this Prospectus is , 1996.
--------
<PAGE>
AVAILABLE INFORMATION
SMT is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and, in accordance
therewith, files reports and other information with the Securities and Exchange
Commission (the "Commission"). Such reports and other information can be
inspected and copied at the Public Reference Section of the Commission at 450
Fifth Street, N.W., Washington, D.C. 20549, and at the Commission's regional
offices at Northwestern Atrium Center, 500 West Madison Street, Suite 1400,
Chicago, Illinois 60661-2511, and Seven World Trade Center, 13th Floor, New
York, New York 10048. Copies of the reports and other information can be
obtained from the Public Reference Section of the Commission, Washington, D.C.
20549, at prescribed rates.
SMT has filed with the Commission a Registration Statement under the
Securities Act of 1933, as amended, with respect to the Securities offered by
this Prospectus. As permitted by the rules and regulations of the Commission,
this Prospectus does not contain all of the information set forth in the
Registration Statement. For further information about SMT and the Securities
offered hereby, reference is made to the Registration Statement and to the
financial statements, exhibits and schedules filed therewith. The statements
contained in this Prospectus about the contents of any contract or other
document referred to are not necessarily complete, and in each instance
reference is made to the copy of such contract or other document filed as an
exhibit to the Registration Statement, each such statement being qualified in
all respects by such reference. Copies of each such document may be obtained
from the Commission at its principal office in Washington, D.C., upon payment of
the charges prescribed by the Commission. Electronic registration statements
made through the Electronic Data Gathering, Analysis, and Retrieval system are
publically available through the Commission's Web site (http://www.sec.gov).
INCORPORATION BY REFERENCE
The following documents filed by the Company with the Commission
pursuant to the Exchange Act are incorporated herein by reference: (a) Annual
Report on Form 10-K for the fiscal year ended December 31, 1995, as amended by
Amendment No. 1 thereto; (b) Quarterly Report on Form 10-Q for the fiscal
quarter ended March 31, 1996, as amended by Amendment No. 1 thereto; (c) Proxy
Statement dated March 28, 1996; and (d) The description of the Company's Common
Stock contained in the registration statement on Form 8-A.
All documents subsequently filed by the Company pursuant to Section
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this
offering shall be deemed to be incorporated by reference in this Prospectus and
to be a part hereof from the respective date of filing of each such document.
Any statement contained in a document incorporated or deemed to be incorporated
by reference herein shall be deemed to be modified or superseded for purposes of
this Prospectus to the extent that a statement contained herein or in any other
subsequently filed document which also is, or is deemed to be, incorporated by
reference herein modifies or supersedes such statement. Any such statement so
modified or superseded shall not be deemed, except as so modified or superseded,
to constitute a part of this Prospectus.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon written or oral request, a copy of any or all of
the documents incorporated by reference herein, other than certain exhibits to
such documents. Requests for such documents should be directed to David A. Zynn,
Chief Financial Officer, SMT Health Services Inc., 10521 Perry Highway, Wexford,
Pennsylvania 15090. The Company's telephone number is (412) 933-3300.
2
<PAGE>
RISK FACTORS
The purchase of the Securities being offered hereby involves a high
degree of risk and substantial dilution. Prospective investors should carefully
consider, among other matters, the following risks and other factors before
making a decision to purchase the Securities.
Significant Leverage and Repayment Obligations
The Company's business is highly capital intensive. The Company has
financed the acquisition of all of its Mobile Magnetic Resonance Imaging ("MRI")
equipment through capital leases and loans and as a result is highly leveraged.
At December 31, 1995, the Company's total liabilities were approximately $17.9
million and its capital was approximately $5.4 million. At March 31, 1996, the
Company's total liabilities were approximately $20.1 million and its capital was
approximately $5.9 million. The Company is therefore subject to the risks
associated with such substantial leverage, including the risk that cash flow may
not be adequate to make required payments on indebtedness. A decrease in
equipment utilization arising from, among other things, cancellation or
nonrenewal of contracts, equipment malfunctions, the inability to effect prompt
and timely repairs to equipment or a reduction in demand for the Company's
equipment or services could materially and adversely affect the Company's
ability to service its indebtedness.
The Company's monthly payments on its capital leases and other long-
term debt were approximately $550,000 as of March 31, 1996. Total payments under
the Company's capital lease obligations and other long-term debt may equal or
exceed minimum revenues receivable under the Company's service contracts if such
contracts are not renewed by healthcare providers, if receivables are not
collected by the Company on a timely basis or if the number of scans or other
services performed fails to meet expected levels. In such case, the Company
would be unable to meet its debt service obligations, and would be in default
under its various loan and lease agreements.
As of December 31, 1995, the Company's current assets were
approximately $5.6 million and its current liabilities were approximately $5.2
million, resulting in a working capital surplus of approximately $400,000. At
March 31, 1996, the Company's current assets were approximately $5.2 million,
and its current liabilities were approximately $5.8 million resulting in a
working capital deficit of $600,000. The change in working capital since year
end is primarily due to the acquisition of a mobile MRI provider during the
first fiscal quarter. Of such liabilities, approximately $4.4 million and $4.9
million represented the current portion of long-term debt and capital lease
obligations as of December 31, 1995 and March 31, 1996 respectively. There can
be no assurance that the Company's revenues will continue to be sufficient to
satisfy the increased lease payments or that such favorable terms will be
available in the future.
Equipment Maintenance, Service and Damage
All of the diagnostic imaging equipment utilized by the Company is
technologically sophisticated and complex, requires regular service and is
subject to unpredictable malfunctions and breakdowns. The Company contracts
with, and relies upon, the equipment manufacturer to provide maintenance
services on a prompt and timely basis. Because diagnostic imaging equipment is
technologically sophisticated, it is uncertain whether and how quickly others
could provide maintenance services if the equipment manufacturers were unable or
unwilling to do so. Consequently, the Company's business might be adversely
affected if the manufacturers stopped providing maintenance services.
Substantially all of the Company's tangible assets consist of
diagnostic imaging equipment, including primarily specially designed mobile MRI
units. Generally, a mobile unit is moved several times a week from one location
to another, and there is always a risk that a traffic accident or automotive
breakdown will occur while the equipment is in transit. Although the Company's
equipment is insured against the risks of damage in an accident, and the Company
is insured for business interruptions resulting from any damage to such
equipment for the period required to repair or replace the equipment, it may not
be possible to repair damaged equipment so that it will achieve its original
level of performance. Substitute or replacement equipment may be unavailable and
the quality of the potential replacement equipment unknown. In addition, there
is no assurance that the Company would receive sufficient insurance proceeds
following any damage to its equipment to fully compensate it for the losses
resulting from such damage or receive business interruption insurance proceeds
to compensate for lost business.
3
<PAGE>
Reimbursement of Health Care Costs
The Company receives payment directly from health care providers,
rather than from private insurers, other third party payors or governmental
entities, for its mobile MRI units. The Company's mobile service contracts with
its customers provide that the Company must be paid within 30 days of providing
its services and are not conditioned upon the receipt of payment by the
healthcare provider. Under current reimbursement regulations, the Company is
unable to bill the insurer or the patient directly for services provided for
hospital inpatients or outpatients. Payment to health care providers by third
party payors for the Company's diagnostic services depends substantially upon
such payors' reimbursement policies. Consequently, those policies have a direct
effect on health care providers' ability to pay for the Company's services and
the Company's level of charges. Mounting concerns about rising health care costs
may cause more restrictive reimbursement policies to be implemented in the
future. Restrictions on reimbursements to health care providers may affect such
providers' ability to pay for the services offered by the Company and could
indirectly adversely affect the Company's financial performance.
Other Reimbursement Matters
Many insurance companies, employers and other payors are increasing
their use of managed care plans such as health maintenance organizations
("HMOs") and preferred provider organizations ("PPOs") as a means of controlling
their healthcare costs. In addition to contracting with selected healthcare
providers to provide healthcare services, often at a discount or on a capitation
basis, such plans engage in strict utilization review activities to more closely
control the utilization of services by their subscribers. There can be no
assurance that the increased use of managed care plans in the Company's service
areas will not affect its level of charges or the demand for its services.
Numerous changes have been made in governmental and commercial
insurance programs in recent years in an effort to reduce the extent to which
these third-party payors absorb increases in medical costs. Some third-party
payors have also experienced difficulties in meeting their payment obligations
whether on a timely basis or otherwise. In addition, a number of bills proposing
to regulate, control or alter the methods of financing and delivering
healthcare, including proposals for a national health insurance program, have
been discussed and introduced in Congress and various state legislatures.
Further, Congress has proposed Medicare/Medicaid Reform which would limit
increases in governmental healthcare expenditures. The effect of any of these
proposals or changes by existing insurers in their reimbursement methodologies
on the healthcare industry and the Company cannot be determined at this time.
Availability of Equipment Financing; Timely Delivery of Equipment
Future acquisitions of equipment will be made pursuant to capital and
operating leases or purchase financing. Leases or loans for mobile MRI equipment
are generally in the original principal amount of approximately $1.8 million to
$2.2 million per unit, depending upon the type, features and options of the
diagnostic imaging equipment leased. The Company's ability to expand is,
therefore, tied to the availability of lease or purchase financing. Although the
Company has in the past been able to procure lease and purchase financing, there
can be no assurance that lenders or equipment leasing companies will continue to
enter into leases or purchase financing with the Company.
The timely delivery of mobile MRI equipment is outside the control of
the Company and significant delays in delivery may materially and adversely
affect the Company. Such delays could arise from, among other things,
manufacturer and delivery delays.
4
<PAGE>
Government Regulation
General. The provision of diagnostic imaging services is subject to a
number of federal, state and local laws, regulations and rules, some of which
are very complex. Although the Company believes that it is currently in
compliance with applicable laws, regulations and rules, some of such laws are
broadly written and subject to little or no interpretation by courts or
administrative authorities. Hence, there can be no assurance that a third party
or governmental agency will not contend that certain aspects of the Company's
operations or procedures are not in compliance with such laws, regulations or
rules or that state agencies or courts would interpret such laws, regulations
and rules in the Company's favor. The sanctions for failure to comply with such
laws, regulations or rules could be denial of the right to conduct business,
significant fines and/or criminal penalties. Additionally, an increase in the
complexity or substantive requirements of such laws, regulations or rules could
adversely affect the Company's business.
Certificate of Need. In addition, several states in which the Company
operates have certificate of need ("CON") laws and regulations that control and
regulate the establishment of healthcare facilities and services and the
acquisition and operation by hospitals and other providers of major equipment
such as MRI units and other diagnostic imaging equipment. In several states in
which the Company operates, a hospital or the Company may need a CON before the
Company can provide its diagnostic imaging services. CON regulations could
inhibit the expansion of the Company's business.
Practice of Medicine. The establishment, marketing and operation of
the diagnostic imaging units are subject to laws prohibiting the practice of
medicine by non-physicians. The Company's employees provide only the technical
services relating to the diagnostic procedures (under the supervision of
licensed physicians) and the related non-medical administrative support
services. Professional medical services, such as the reading of the diagnostic
imaging studies and related diagnosis, are separately provided by licensed
physicians. The Company does not employ any physicians to provide medical
services. There can be no assurance, however, that state authorities or courts
will not determine that the Company's services and/or relationships with
providers constitute the unauthorized practice of medicine by the Company.
Fraud and Abuse Laws. The Social Security Act and certain provisions
of state law provide civil and criminal penalties for persons who knowingly and
willfully solicit, pay, offer or receive any remuneration, directly or
indirectly, as an inducement to make a referral of a patient for services or
items for which payment may be made under the Medicare or Medicaid programs.
Often termed "fraud and abuse" or "anti-kickback" laws, the provisions have been
broadly interpreted by the courts.
The Office of Inspector General of the Department of Health and Human
Services ("HHS") has issued regulations specifying certain business arrangements
and payment practices involving providers or other entities, such as the
Company, which will not be considered prohibited activities. Commonly termed
"safe harbor regulations," the regulations set forth certain standards which, if
satisfied, will ensure that the arrangement will not be subject to criminal
prosecution or civil sanctions under the fraud and abuse laws. Failure to
satisfy the safe harbors in and of itself does not render an arrangement
illegal. The Company believes it is in compliance with the safe harbor
regulations applicable to its current operations.
One principal focus of the fraud and abuse laws has been on
arrangements in which profit distributions are made by a partnership or other
business venture for health-related items or services to investors who make or
are otherwise in a position to influence referrals of Medicare or Medicaid
patients to the venture. Where such arrangements exist, a question is raised as
to whether the profit distributions are illegal payments in exchange for
referrals. Certain safe harbors set forth criteria which, if met, will insure
that investors in business ventures for health-related items or services will
not be subject to scrutiny under the fraud and abuse laws.
5
<PAGE>
One safe harbor protects profit distributions to investors made by
publicly traded companies with tangible assets of more than $50 million. At
present, the Company does not satisfy the asset threshold for protection under
this safe harbor.
Another safe harbor covers investment interests in small entities. The
conditions for compliance with this safe harbor include, among other things,
requirements that no more than 40% of the investment interests of each class of
investments in the entity may be held by persons who are in a position to make
or influence referrals (including hospitals and physicians), furnish items or
services to the entity or otherwise generate business for the entity, so-called
"tainted investors," and that no more than 40% of the entity's gross revenues
may come from referrals, items or services furnished or business otherwise
generated by "tainted investors." Unless a large percentage of the Company's
Common Stock or Warrants are held by "tainted investors," it would appear that
investments in the Company will fall within the safe harbor for investment
interests.
None of the Company's mobile MRI activities are carried out through
partnerships or other ventures with hospitals, physicians or other third
parties.
The laws involving fraud and abuse and the safe harbor regulations are
currently in a rapid state of development and it is difficult to provide a clear
analysis of the risks in this area. There can be no assurance that enforcement
agencies or courts will determine that any existing arrangements comply with all
applicable laws and regulations.
Other Patient Referral Restrictions. Additionally, Pennsylvania, as
well as other states in which the Company operates, prohibits the referral of
Medicaid patients for services or items by a provider in which the referring
physician has an ownership interest. Certain states do not restrict patient
referrals but do require the disclosure to a patient by the referring physician
of a financial interest in a facility or vendor to which the patient is being
referred for services or items.
Stark II. The Omnibus Budget Reconciliation Act of 1993 enacted new
federal anti-referral legislation, more commonly known as "Stark II" after its
prime sponsor, Rep. Fortney "Pete" Stark (D. Calif.). Effective January 1, 1995,
Stark II bans referrals by physicians of Medicare and Medicaid patients to
entities for certain designated health services, including MRI services, if a
physician or immediate family member has a prohibited financial relationship
with the entity providing the service. A financial relationship is generally
defined as an ownership or investment interest in or compensation arrangement
with the entity, subject to certain exceptions. Penalties include nonpayment for
services rendered pursuant to a prohibited referral, civil money penalties and
fines and possible exclusion from the Medicare and Medicaid programs. The
Company believes it is currently in compliance with the requirements of Stark
II. However, there can be no assurance that enforcement agencies or courts will
determine that existing arrangements comply with all applicable laws and
regulations.
Need for Additional Financing
The Company expects that its current cash balances, future cash flows
anticipated to be generated from operations and currently available equipment
financing arrangements will be sufficient to fund the Company's operations
through at least fiscal year 1997. This estimate is based on certain
assumptions, including the maintenance of expenses and cash flows from
operations at historical levels. There can be no assurance that these
assumptions will be realized or that a sufficient level of equipment utilization
will be attained to fund operations after the stated period. The failure to
achieve these assumptions may decrease the period of time for which the Company
estimates that these funds will be sufficient.
6
<PAGE>
Reliance on Key Personnel
The Company's success depends in large part upon a number of key
management personnel and technical employees. The loss of the services of one or
more of its management personnel, in particular Jeff D. Bergman, Daniel Dickman,
David Zynn and David Spindler, could have a material adverse effect on the
Company. The Company has key man life insurance covering Messrs. Bergman,
Dickman and Spindler.
The ability of the Company to attract and retain qualified technicians
to operate the diagnostic imaging equipment is crucial to the operations of the
Company. Such technicians are in short supply and are typically attracted to
nonmobile facilities which provide predictable locations and work schedules. In
contrast, mobile facilities provide very unpredictable work schedules and
constantly changing locations which may not be attractive to a large portion of
technicians. Therefore, the Company may experience some difficulty finding
qualified technicians for its mobile MRI units. The Company believes its future
success will depend in part on its ability to attract and retain highly skilled
employees. To date, the Company has been able to attract sufficient technicians,
although there can be no assurance that this will continue in the future.
Technological Change and Obsolescence
The Company's services require the use of state-of-the-art medical
diagnostic equipment that has been characterized by rapid technological
advances. Although the Company believes that the equipment it provides can be
upgraded to maintain its state-of-the-art character, the development of new
technologies or refinements of existing ones might make the Company's existing
equipment technologically or economically obsolete, or cause a reduction in the
value of, or reduce the need for, the Company's equipment. Diagnostic imaging
equipment is currently manufactured by numerous companies. Competition among
manufacturers for a greater share of the diagnostic imaging equipment market may
have the effect of generating greater technological advances in the capacity of
this new equipment. Consequently, the obsolescence of the Company's equipment
may be accelerated. Although the Company is aware of no substantial
technological change, should such change occur there can be no assurance that
the Company will be able to acquire the new or improved equipment which may be
required to service its customers.
Other Requirements Concerning Licensing, Permits and Approvals
Most states do not currently license MRI providers such as the
Company. Hospitals with which the Company has contracted are subject to a
variety of regulations and standards of state licensing and other authorities
and accrediting bodies such as the Joint Commission for the Accreditation of
Healthcare Organizations ("JCAHO"). As an outside vendor, the Company may be
required to comply with such regulations and standards to enable the hospitals
with which it has contracted to maintain their permits, approvals and
accreditations.
There can be no assurance that future changes in the laws and
regulations relating to the delivery of healthcare items and services may
require the Company or any venture involving the Company to obtain and maintain
certain governmental approvals for continued operations. It is not possible to
predict the effect of such changes in the law on the Company at this time.
For the most part, the Company's employees need not have special
licenses. Drivers of trucks must have certain special driving licenses. MRI
technicians are not required to have licenses in any of the states in which the
Company does business. However, many states are holding discussions to require
such licensing and to require continuing education. The Company believes that
any such licensing requirement would not have any adverse impact on the Company.
7
<PAGE>
Competition
The healthcare industry in general, and the market for diagnostic
imaging services in particular, is highly competitive. Certain competitors
operate fixed-site centers and mobile units in the Company's current service
area. Some competitors may have financial resources substantially greater than
those of the Company which may give them advantages in negotiating equipment
acquisitions and responding quickly to new demand or new technology. In
addition, hospitals, private clinics and radiology practices in the Company's
service area have in-house equipment which competes with the Company. MRI also
competes with less expensive diagnostic imaging devices and procedures which may
provide similar information to the physician. Existing healthcare providers who
are currently customers of the Company may purchase diagnostic imaging equipment
if the cost of such equipment decreases or if their volume of patients increases
to the point where it becomes cost-effective to own and operate their own
equipment.
Insurance
The Company carries workers' compensation insurance, comprehensive and
general liability insurance, business interruption, fire and allied perils
coverage in amounts deemed adequate by the Company. The Company requires that
its healthcare customers maintain professional liability insurance and the
Company maintains its own professional liability policy. There can be no
assurance that claims will not exceed the amounts of insurance coverage, that
the cost for such coverage will not increase to the extent that the Company will
be forced to self-insure a substantial portion of this risk, or that such
coverage will not be reduced or become unavailable.
Control of Company
The Company's officers and directors as a group beneficially own
approximately 33.5% of the Company's Common Stock and are able to exert
considerable influence over the affairs and policies of the Company.
Dividends
The Company has not paid, and does not anticipate paying in the
foreseeable future, cash dividends on its Common Stock.
On July 10, 1995, the Company paid a 5% stock dividend to all holders
of record of its Common Stock as of June 30, 1995.
Shares Eligible for Future Sale
As of the date hereof, there were 3,087,225 shares of Common Stock
issued and outstanding, excluding 1,793,348 shares issuable by the Company upon
exercise of certain other warrants, 126,000 shares of Common Stock issuable upon
exercise of an option, 100,000 shares issuable upon exercise of the Commonwealth
Warrants and 949,100 shares issuable to certain officers and directors upon
exercise of options and rights held by them. Of such 3,087,225 shares of Common
Stock, 1,449,000 shares of Common Stock were sold in the IPO, 693,000 shares
were sold by certain selling stockholders pursuant to registration statements
under the Securities Act of 1933, as amended (the "Securities Act"), and 438,825
shares were issued pursuant to the exercise of options under registration
statements under the Securities Act. The remaining 506,400 shares of Common
Stock are "restricted securities" (as that term is defined under Rule 144
promulgated under the Securities Act) held by four (4) persons. The Company
believes that all but 120,000 of such shares have been held for at least two
years and may be sold in accordance with Rule 144. The sale, or availability for
sale, of substantial amounts of Common Stock in the public market, or any
additional offering of Common Stock, could adversely affect the prevailing
market price of the Common Stock and could impair the Company's ability to raise
additional capital through the sale of its equity securities.
8
<PAGE>
Sale of Discontinued Operations
As previously disclosed in the Company's public filings, the Company
implemented a plan which it believed would lead to the divestiture of its
outpatient healthcare centers during 1994. On October 31, 1994, the Company sold
substantially all of the assets of its radiation therapy center located in
Auburn, Washington, for a total sale price of approximately $1.3 million. The
sale of the center did not result in a gain or loss and resulted in cash
proceeds to the Company of $400,000. The Company remains obligated on
approximately $400,000 of capital leases as of March 31, 1996. The buyer has
agreed to use its best efforts to have the Company released from these leases
and has secured its obligations to the Company to perform these leases through a
pledge of certain assets in favor of the Company.
On June 30, 1995, the Company completed the sale of substantially all
of the assets of its remaining outpatient healthcare center, Airport Regional
Imaging Center, located in Coraopolis, Pennsylvania, as well as its sixty
percent ownership and general partner interests in all of its cardiac care
centers to Cardiac Fitness Inc., or an affiliate thereof, for a total sale price
of approximately $600,000, including cash and net trade receivables of
approximately $500,000 and a note of $100,000. Although the buyer assumed all
future operating liabilities of the healthcare center, the Company remains
obligated on approximately $700,000 of capital leases as of March 31, 1996. The
buyer has agreed to use its best efforts to have the Company released from these
leases and has secured its obligations to the Company to perform these leases
through a pledge of stock and certain assets in favor of the Company.
The sale of the healthcare center, which had previously been treated
as a discontinued operation, did not result in a gain or loss. The sale of the
sixty-percent ownership and general partnership interests in the cardiac care
centers which were treated as continuing operations, resulted in an approximate
$50,000 pre-tax gain which was recorded in the second quarter of 1995.
--------------------------------
Although it will have no legal obligation to do so, any underwriter
participating in this offering may, from time to time, act as a market maker or
otherwise effect transactions in the Company's securities. Such underwriter, or
other underwriters participating in the offering, if any, may be dominating
influences in the market for the Warrants. The price and liquidity of the
Warrants may be affected by the degree, if any, of such underwriter
participation in the market. Such activities, if commenced, may be discontinued
at any time or from time to time and may require the Company to establish new
market makers.
--------------------------------
9
<PAGE>
THE COMPANY
The Company is primarily engaged in the business of operating mobile
MRI units. MRI involves the use of high strength magnetic fields and radio waves
to produce cross-sectional images of the anatomy. MRI facilitates the diagnosis
in the early stages of disease without the need for exploratory surgery or other
invasive procedures. MRI has become a preferred diagnostic tool of the medical
profession because it is non-invasive and its images are generally better
defined and more precise than those produced by other diagnostic imaging tests,
without the use of harmful ionizing radiation, such as that produced by computed
axial tomography ("CAT") scans and standard x-rays.
The Company provides mobile MRI services to healthcare providers,
which consist primarily of small and medium size hospitals. Including a new MRI
unit acquired in February 1996 and the purchase of two new units from another
mobile provider in March 1996, the Company currently operates fourteen mobile
MRI units which service healthcare providers located in Pennsylvania, North
Carolina, West Virginia, Ohio, Virginia and Kentucky. The MRI equipment is
transported in specially designed vans that are driven to the healthcare
provider's facility where the imaging occurs. The healthcare provider pays the
Company on a per scan basis for the use of the equipment. The healthcare
providers utilizing the Company's services have a need for MRI services, but do
not own their own equipment due to insufficient patient volume to justify a
full-time fixed MRI unit, the high cost of owning and operating such equipment,
the lack of expertise in this highly specialized field or due to regulatory
constraints.
The Company was formed in November 1991 to merge with Shared Medical
Technologies, Inc., a Pennsylvania corporation incorporated in 1987 ("Old SMT")
and Shared MRI-4, Inc., a Pennsylvania corporation ("MRI-4"), and to acquire
substantially all of the assets and assume substantially all of the liabilities
of Shared MRI-1, L.P., a Pennsylvania limited partnership ("MRI-1") and Shared
MRI-3, L.P., a Pennsylvania limited partnership ("MRI-3") (Old SMT, MRI-4, MRI-1
and MRI-3 are collectively referred to as the "SMT Group"), each of which leased
one, and in the case of Old SMT, two, mobile MRI units (the "Consolidation"). As
of November 1991, all of the four entities comprising the SMT Group were owned
or controlled by Jeff D. Bergman, Daniel Dickman and Mark A. DeSimone, who
(along with Mr. DeSimone's spouse) are holders of 564,575 shares, or
approximately 18%, of the Company's outstanding Common Stock. Messrs. Bergman,
Dickman and DeSimone in the aggregate are beneficial owners of an additional
538,500 shares through rights to acquire the Company's Common Stock. The assets
of MRI-1 and MRI-3 were acquired by the Company in exchange for an aggregate of
$1,300,000 in notes (the "LP Notes"), the assumption of approximately $2,600,000
of liabilities of the partnerships (primarily relating to the capital leases for
the MRI equipment) and 99,950 Warrants. In March 1992, the LP Notes were
redeemed, utilizing a portion of the net proceeds of the IPO.
In March 1992, the Company effectuated an underwritten initial public
offering (the "IPO") of Units, each Unit consisting of one share of Common Stock
and one Public Warrant to purchase a share of Common Stock for $7.00
(subsequently adjusted to $6.67 as a result of a stock dividend). The Units
traded on Nasdaq from March 4, 1992, until October 15, 1992. On October 16, 1992
(the "Separation Date"), the Common Stock and Public Warrants began to trade
separately on Nasdaq under the symbols "SHED" and "SHEDW," respectively, and the
Units were delisted from trading on Nasdaq.
During November 1995, the Company's Common Stock and Public Warrants
began to trade on the Nasdaq National Market under the symbols SHED and SHEDW,
respectively.
The Company's executive offices are located at 10521 Perry Highway,
Wexford, Pennsylvania 15090, and its telephone number is (412) 933-3300. Unless
the context requires otherwise, with respect to events occurring prior to the
Consolidation, the "Company" may refer to one or more of the entities comprising
the SMT Group.
10
<PAGE>
USE OF PROCEEDS
The Company will not receive any of the proceeds from the sale of the
Commonwealth Warrants offered hereby by the Selling Stockholders.
SELLING STOCKHOLDERS
The Commonwealth Warrants to purchase 100,000 shares of Common Stock
at an initial exercise price of $4.47 were issued to Commonwealth Associates as
consideration for their engagement as the Company's investment banker.
The following table sets forth information with respect to the
beneficial ownership of Warrants by Commonwealth Associates as of the close of
business on April 30, 1996, all of which may be offered from time to time
hereby. As a registered broker-dealer and market-maker in the Common Stock and
the Public Warrants, Commonwealth Associates may, from time to time, acquire and
dispose of beneficial ownership of other Company securities.
<TABLE>
<CAPTION>
Beneficial Ownership
---------------------------------------
Name of Selling Stockholder Number of Warrants Percentage of Class
- --------------------------- ------------------ -------------------
<S> <C> <C>
Commonwealth Associates 50,000 50
733 Third Avenue
New York, NY 10017
Andres V. Bello/1/ 100,000 100
c/o Commonwealth Associates
733 Third Avenue
New York, NY 10017
</TABLE>
- -------------------------
/1/Includes 50,000 shares owned by Commonwealth Associates which Mr. Bello may
be deemed to own as a Managing Director of Commonwealth Associates.
The following sets forth information regarding any position, office or
material relationship that each of the Selling Stockholders has had with the
Company during the past three years.
The Company signed a six-month agreement retaining Commonwealth
Associates ("Commonwealth") as its investment banking firm. Commonwealth, a New
York based investment banking firm specializing in serving the financial needs
of emerging growth companies, was engaged to assist the Company in establishing
a long-term financial strategy and in evaluating possible transactions involving
other mobile diagnostic providers. In addition to a normal retainer, the
Company granted to Commonwealth 100,000 five-year Warrants to purchase the
Company's Common Stock at $4.47, the closing bid price of the Common Stock the
day the Agreement was executed. The Agreement with Commonwealth expired on
April 10, 1996.
11
<PAGE>
DESCRIPTION OF SECURITIES
Commonwealth Warrants
Pursuant to a Warrant Agreement dated October 9, 1995, Commonwealth
Associates ("Commonwealth") received warrants to purchase up to 100,000 shares
of common stock of the Company, par value $.01 per share (the "Common Stock"),
at an initial exercise price of $4.47 per share (the "Commonwealth Warrants")
from the date of issuance until the close of business on October 9, 2002.
Each Common Warrant holder may exercise such Commonwealth Warrant by
surrendering the certificate evidencing such Commonwealth Warrant, with the
subscription form on the reverse side of such certificate properly completed and
executed, together with payment of the exercise price to the Company at its
principal offices. The exercise price will be payable in cash in United States
dollars or by check in United States dollars, or a combination of both, payable
to the Company. If less than all the of the Commonwealth Warrants evidenced by a
Commonwealth Warrant certificate are exercised, a new certificate will be issued
for the remaining number of Commonwealth Warrants. The Commonwealth Warrants are
exchangeable for their value in Common Stock based upon the closing price of
such Common Stock as quoted on the Nasdaq NMS on the date of exchange.
The Company is not required to issue fractional Commonwealth Warrants
representing fractions of shares of Common Stock, and all fractional interests
shall be eliminated by rounding any fraction up to the nearest whole number of
shares of Common Stock.
The Warrant Agreement contains certain registration rights including
demand rights and a piggyback registration provision in which the Company will
provide notice to the holders of the Commonwealth Warrants if the Company
proposes to register any of its securities.
The exercise price and the number and kind of shares of Common Stock
or other securities purchasable upon exercise of any Commonwealth Warrants and
the number of Commonwealth Warrants are subject to adjustment upon the
occurrence of certain events, including: any subdivision or combination of the
outstanding shares of the Company. No adjustment shall be made if the amount of
the adjustment is less than $.02 per share; provided that any such adjustment
not required to be made will be carried forward and taken into account in any
subsequent adjustment.
In the case of any reclassification or change in outstanding shares of
Common Stock (other than a change in par value to no par value, or from no par
value to par value, or as a result of a consolidation or merger which does not
result in any reclassification, capital reorganization or other similar change
in the outstanding Common Stock) or a sale or conveyance to another corporation
of the property of the Company as, or substantially as, an entirety, each
Warrant will thereupon become exercisable only for the kind and number of shares
of stock or other securities, assets, or cash to which a holder of the number of
shares of Common Stock purchasable (at the time of reclassification,
reorganization, consolidation, merger or sale) upon exercise of such
Commonwealth Warrant would have been entitled upon such reclassification,
reorganization, consolidation, merger or sale. In the case of a merger of the
Company into another corporation or any other cash transaction of the type
mentioned above, the effect of these provisions would be that the holder of a
Commonwealth Warrant would thereafter be limited to exercising such Commonwealth
Warrant at the exercise price in effect at such time for the amount of cash per
share that a Commonwealth Warrant holder would have received had such holder
exercised such Commonwealth Warrant and received shares of Common Stock
immediately prior to the effective date of such cash merger or transaction.
Depending upon the terms of such cash merger or transaction, the aggregate
amount of cash so received could be more or less than the exercise price of the
Commonwealth Warrant.
12
<PAGE>
Without the consent of the Company, the Commonwealth Warrants may only
be transferred or assigned by Commonwealth, in whole or in part, to a successor
or affiliate thereof or to an officer, director or employee of Commonwealth or
any successor or any affiliate thereof.
The holders of the Commonwealth Warrants will not have the right to
vote or to consent or to receive notice as a stockholder in respect of any
meetings of stockholders.
The Warrant Agreement contains provisions permitting the Company and
Commonwealth to supplement or amend the Warrant Agreement without the approval
of any holders of the Commonwealth Warrants in order to cure any ambiguity, to
correct or supplement any provision contained therein which may be defective or
inconsistent with any other provisions therein, or to make any other provisions
which the Company and Commonwealth may deem necessary or desirable and which
does not adversely affect the interests of the Commonwealth Warrant holders.
The Company will reserve and keep available out of its authorized but
unissued shares a sufficient number of shares of Common Stock for issuance on
exercise of the Commonwealth Warrants. The Common Stock issuable on exercise of
the Commonwealth Warrants will be, when issued, fully paid and nonassessable.
PLAN OF DISTRIBUTION
The Commonwealth Warrants offered hereby may be sold from time to time
directly by a Selling Stockholder or by certain transferees or affiliates of a
Selling Stockholder. Alternatively, such person may from time to time offer
such Commonwealth Warrants through underwriters, dealers or agents. The
distribution of Commonwealth Warrants by such person may be effected in one or
more transactions that may take place on the over-the-counter market (if any),
including ordinary broker's transactions, in privately-negotiated transactions,
through sales to one or more broker-dealers for resale of such shares as
principals, at market prices (if any) prevailing at the time of sale, at prices
related to such prevailing market prices or at negotiated prices, or otherwise.
Usual and customary or specifically negotiated brokerage fees or commissions may
be paid by such person in connection with such sales of the Commonwealth
Warrants. Such person and intermediaries through whom the Commonwealth Warrants
are sold may be deemed "underwriters" within the meaning of the Securities Act
with respect to the Commonwealth Warrants offered, and any profits realized or
commissions received may be deemed underwriting compensation. The Company has
agreed to indemnify Commonwealth Associates and Andres V. Bello against certain
liabilities, including liabilities under the Securities Act.
EXPERTS
The financial statements and the related financial statement schedules
incorporated in this Prospectus by reference from the Company's Annual Report on
Form 10-K, as amended by Amendment No. 1 thereto, as of and for the years ended
December 31, 1995 and December 31, 1994, have been audited by KPMG Peat Marwick
LLP; and for the year ended December 31, 1993 have been audited by Deloitte &
Touche LLP, independent auditors, as stated in their respective reports which
are incorporated herein by reference, and have been so incorporated in reliance
upon the reports of such firms given upon their authority as experts in
accounting and auditing.
Certain legal matters with respect to the Warrants offered hereby have
been passed upon for the Company by Buchanan Ingersoll Professional Corporation.
13
<PAGE>
PART II
Information Not Required in Prospectus
Item 14. Other Expenses of Issuance and Distribution
The estimated expenses of this offering in connection with the
issuance and distribution of the securities being registered, all of which
are to be paid by the Registrant, are as follows:
SEC Registration Fee............................. $ 2,022.00
NASD Filing Fee.................................. 2,411.61
Printing and Engraving........................... 75,000.00
Accounting Fees and Expenses..................... 185,000.00
Legal Fees and Expenses.......................... 290,000.00
Blue Sky Fees and Expenses....................... 45,000.00
Underwriter's Non-Accountable Expense Allowance.. 180,000.00
Transfer Agent's Fees and Expenses............... 5,000.00
Miscellaneous Expenses........................... 6,520.85
-----------
Total............................................ $780,954.46
===========
Item 15. Indemnification of Directors and Officers
The Company's Certificate of Incorporation provides, in part, that
the Company shall indemnify its directors, officers, employees and agents
to the fullest extent permitted by the Delaware General Corporation Law
("DGCL").
The DGCL permits Delaware corporations to indemnify their directors
and officers against all reasonable expenses incurred in the defense of
any lawsuit to which they are made parties by reason of being directors or
officers, in cases of successful defense, and against such expenses in
other cases, subject to specified conditions and exclusions. Such
indemnification is not exclusive of any other rights to which those
indemnified may be entitled under any by-law, agreement, vote of
stockholders or otherwise.
Pursuant to the DGCL, the Company's Certificate of Incorporation
contains a provision eliminating the personal liability of a director to a
corporation or its stockholders for monetary damages for breach of, or
failure to perform, any duty resulting solely from his status as a
director, except with respect to (a) willful failure to deal fairly with
the corporation or its stockholders where a director has a material
conflict of interest, (b) a violation of criminal law unless the director
had reasonable cause to believe his conduct was lawful, (c) a transaction
yielding an improper personal profit, and (d) willful misconduct. The
foregoing limitation of a director's personal liability also is
inapplicable to situations wherein a director has voted for, or assented
to the declaration of, a dividend, repurchase of shares, distribution, or
the making of a loan to an officer or director, in each case where the
same occurs in violation of applicable law.
II-1
<PAGE>
Item 16. Exhibits
2.1 -- Merger Agreement among Shared Medical Technologies, Inc.,
Shared MRI-4, Inc. and the Registrant
2.2 -- Asset Purchase Agreement dated as of November 27, 1991,
between the Registrant and Shared MRI-1, L.P.
2.3 -- Asset Purchase Agreement dated as of November 27, 1991,
between the Registrant and Shared MRI-3, L.P.
2.4 -- Amended and Restated Stock Purchase Agreement dated
November 27, 1991, among the Registrant, DVI Financial
Services Inc. and Shared Medical Technologies, Inc.
2.5 -- Asset Purchase Agreement between Universal Health Centers,
Inc. and SMT Health Services Inc. dated as of October 31,
1994
2.6 -- Agreement of Purchase and Sale By and Between Airport
Regional Imaging Center, L.P. and SMT Cardiac Corp., as
Seller, and C.F. Services, Inc. and C.F. Airport Health
Services, Inc., as Buyers (and related schedules; Equipment
Sublease by and between Airport Regional Imaging Center,
L.P., and C.F. Airport Health Services, Inc., dated June 30,
1995; Credit Agreement dated June 30, 1995; Security
Agreement dated June 30, 1995; Pledge of Securities Agreement
dated June 30, 1995; and Continuing Agreement of Guaranty and
Suretyship including Authority to Confess Judgment after
Default)
2.7 -- Agreement between Shared Medical Enterprises and SMT Health
Services Inc. dated July 1, 1995
4.1 -- Certificate of Incorporation of the Registrant, as amended
4.2 -- By-laws of the Registrant
4.3 -- Unit Purchase Option Agreement
4.4 -- Warrant Agreement
4.5 -- Warrant Agreement -- Commonwealth Associates
4.6 -- Rights Agreement between SMT Health Services Inc. and
American Stock Transfer & Trust Company, as Rights Agent,
dated November 8, 1995
5.1 -- Opinion of Buchanan Ingersoll Professional Corporation
23.1 -- Consent of Buchanan Ingersoll Professional Corporation
23.2 -- Independent Auditors Consent
23.3 -- Independent Auditors Consent
24.1 -- Power of Attorney
II-2
<PAGE>
Item 17. Undertakings
The Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are
being made, a post-effective amendment to this Registration
Statement to include any material information with respect to
the plan of distribution not previously disclosed in the
Registration Statement or any material change to such
information in the Registration Statement.
(2) That, for the purpose of determining any liability
under the Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities
at the time shall be deemed to be the initial bona fide offering
thereof.
(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain
unsold at the termination of the offering.
The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of
the registrant's annual report pursuant to section 13(a) or section 15(d)
of the Securities Exchange Act of 1934 (and, where applicable, each filing
of an employee benefit plan's annual report pursuant to section 15(d) of
the Securities Exchange Act of 1934) that is incorporated by reference in
the registration statement shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of
such securities at that time shall be deemed to be the initial bona fide
offering thereof.
Insofar as indemnification for liabilities arising under the Act may
be permitted to directors, officers and controlling persons of the
Registrant pursuant to the provisions of its By-laws, of the DGCL, or
otherwise, the Registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other
than the payment by the issuer of expenses incurred or paid by a director,
officer of controlling person of the Registrant in the successful defense
of any action, suit or proceeding) is asserted by such director, officer
or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has
been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
II-3
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing on Form S-3 and has duly caused
this Amendment to the Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the Borough of Wexford,
Commonwealth of Pennsylvania, on the 14th day of June, 1996.
SMT HEALTH SERVICES INC.
By: /s/ Jeff D. Bergman
----------------------------------
Jeff D. Bergman, President
KNOW ALL MEN BY THESE PRESENTS that each person whose signature
appears below constitutes and appoints Jeff D. Bergman, Daniel Dickman and
David A. Zynn, and each of them, his true and lawful attorney-in-fact and
agent, with full power of substitution and resubstitution, for him and in
his person's name, place and stead, in any and all capacities to sign any
and all amendments (including post-effective amendments) to this
Registration Statement and to file the same, with all exhibits thereto,
and all other documents in connection therewith, with the Securities and
Exchange Commission, granting unto each said attorney-in-fact and agent
full power and authority to do and perform each and every act in person,
hereby ratifying and confirming all that said attorneys-in-fact and
agents, or either of them or their or his substitute or substitutes may
lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the
capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ Jeff D. Bergman
____________________ President, Chief Executive June 14, 1996
Jeff D. Bergman Officer and Chairman of the
Board (Principal Executive
Officer)
/s/ David A. Zynn
____________________ Chief Financial Officer June 14, 1996
David A. Zynn (Principal Financial and
Accounting Officer)
*
____________________ Executive Vice President June 14, 1996
Daniel Dickman and Director
*
____________________ Director June 14, 1996
Alan Novich
___________________ Director
Gerald Cohn
*
____________________ Director June 14, 1996
David J. Malone
*By: /s/ Jeff Bergman
----------------------------------
Jeff D. Bergman -Attorney-in-Fact
II-4
<PAGE>
EXHIBIT INDEX
-------------
<TABLE>
<CAPTION>
Exhibit No. Reference
----------- ---------
<S> <C>
2.1 Merger Agreement among Shared Exhibit 2.1 of the Registrant's Registration Statement
Medical Technologies, Inc. Shared on Form S-1 (Registration No. 33-44329) is incorporated
MRI-4, Inc. and the Registrant herein by reference.
2.2 Asset Purchase Agreement dated as of Exhibit 2.2 of the Registrant's Registration Statement on Form S-1
November 27, 1991, between the (Registration No. 33-44329) is incorporated herein by reference.
Registrant and Shared MRI-3, L.P.
2.3 Asset Purchase Agreement dated as of Exhibit 2.3 of the Registrant's Registration Statement on Form S-1
November 27, 1991, between the Registrant (Registration No. 33-44329) is incorporated herein by reference.
and Shared MRI-3, L.P.
2.4 Amended and Restated Stock Purchase Exhibit 2.4 of the Registrant's Registration Statement on Form S-1
Agreement dated November 27, 1991, (Registration No. 33-44329) is incorporated herein by reference.
among the Registrant, DVI Financial
Services Inc. and Shared Medical
Technologies, Inc.
2.5 Asset Purchase Agreement between Exhibit 10.8 of the Registrant's Quarterly Report on Form 10-Q for the
Universal Health Centers, Inc. and quarter ended September 30, 1994, is incorporated herein by reference.
and SMT Health Services Inc. dated
as of October 31, 1994
2.6 Agreement of Purchase and Sale By and Exhibit 10.02 of the Registrant's Quarterly Report on Form 10-Q for the
Between Airport Regional Imaging Center, quarter ended June 30, 1995, is incorporated herein by reference.
L.P. and SMT Cardiac Corp., as Seller, and
C.F. Services, Inc. and C.F. Airport Health
Services, Inc., as Buyers (and related
schedules; Equipment Sublease by and between
Airport Regional Imaging Center, L.P., and
C.F. Airport Health Services, Inc., dated
June 30, 1995; Credit Agreement dated June
30, 1995; Security Agreement dated June 30,
1995; Pledge of Securities Agreement dated
June 30, 1995; and Continuing Agreement of
Guaranty and Suretyship including Authority
to Confess Judgment after Default)
2.7 Agreement between Shared Medical Exhibit 10.03 of the Registrant's Quarterly Report on Form 10-Q for the
Enterprises and SMT Health Services quarter ended June 30, 1955, is incorporated herein by reference.
Inc. dated July 1, 1995
4.1 Certificate of Incorporation of the Exhibit 3.1 of the Registrant's Registration Statement on Form S-1
Registrant, as amended (Registration No. 33-44329) is incorporated herein by reference.
</TABLE>
<PAGE>
<TABLE>
<S> <C>
4.2 By-laws of the Registrant Exhibit 3.2 of the Registrant's Registration Statement on Form S-1
(Registration No. 33-44329) is incorporated herein by reference.
4.3 Unit Purchase Option Agreement Exhibit 4.1 of the Registrant's Annual Report on Form 10-K for the fiscal
year ended December 31, 1992, is incorporated herein by reference.
4.4 Warrant Agreement Exhibit 4.2 of the Registrant's Annual Report on Form 10-K for the fiscal
year ended December 31, 1992, is incorporated herein by reference.
4.5 Warrant Agreement - Previously filed herewith.
Commonwealth Associates
4.6 Rights Agreement between SMT Health Exhibit 1 of the Registrant's Registration Statement on Form 8-A, Amendment
Services Inc. and American Stock No. 1, filed on December 6, 1995
Transfer & Trust Company, as Rights
Agent, dated November 8, 1995
5.1 Opinion of Buchanan Ingersoll Filed herewith.
Professional Corporation
23.1 Consent of Buchanan Ingersoll Contained in their opinion filed as Exhibit 5.1.
Professional Corporation
23.2 Independent Auditors Consent Filed herewith.
23.3 Independent Auditors Consent Filed herewith.
24.1 Power of Attorney Previously filed herewith.
</TABLE>
<PAGE>
EXHIBIT 5.1
June 14, 1996
Board of Directors
SMT Health Services Inc.
10521 Perry Highway
Wexford, PA 15090
Re: Legality of Securities
----------------------
Ladies and Gentlemen:
We have acted as counsel to SMT Health Services Inc., a Delaware corporation
(the "Corporation"), in connection with the registration of 3,494,623 shares of
common stock, par value $.01 per share (the "Shares") of the Corporation, the
registration of 214,450 Warrants (the "Warrants") of the Corporation, and the
registration of 100,000 warrants of the Corporation (the "Commonwealth
Warrants"), to be offered pursuant to the Registration Statement on Form S-3
filed with the Securities and Exchange Commission at File Nos. 33-44329, 33-
86920 and 33-80571 (the "Registration Statement"). Each capitalized term used
herein without being defined herein shall have the meaning ascribed to it in the
Registration Statement.
As such counsel, we have reviewed the Corporation's (i) Certificate of
Incorporation, as amended; (ii) By-laws; (iii) corporate proceedings in
connection with the issuance of the Shares, Warrants, Commonwealth Warrants,
options under various option plans, and any other securities contained in the
Registration Statement; (iv) certificate executed and delivered by certain
officers of the Corporation (the "Officers' Certificate"); and (v) such other
documents, records, certificates of public officials, statutes and decisions as
we deemed necessary to express the opinions contained herein. In the examination
of such documents, we have assumed the genuineness of all signatures and the
authenticity of all documents submitted to us as originals and the conformity to
those original documents of all documents submitted to us as certified or
photostatic copies.
Based on the foregoing, we are of the opinion that when the Registration
Statement shall have been declared effective by order of the Securities and
Exchange Commission, and when the warrants or options pursuant to which the
Shares or Warrants are to be issued are properly exercised in accordance with
the terms of the relevant warrant agreements, warrant plans, stock option plans,
stock option agreements, or any other agreements relating to the issuance of
such securities, then the Shares, Warrants and Commonwealth Warrants, when
offered and sold under and in accordance with the Registration Statement, will
be validly issued, fully paid and non-assessable.
We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement and the reference to this firm under the caption
"Experts" contained therein and elsewhere in the Registration Statement. This
consent is not to be construed as an admission that we are a party whose consent
is required to be filed with the Registration Statement under the provisions of
the Act.
BUCHANAN INGERSOLL
PROFESSIONAL CORPORATION
By: /s/ Ronald Basso
<PAGE>
EXHIBIT 23.2
Consent of Independent Auditors
The Board of Directors
SMT Health Services Inc.:
We consent to the use of our report incorporated herein by reference and to the
reference to our firm under the heading "Experts" in the prospectus.
KPMG Peat Marwick LLP
Pittsburgh, Pennsylvania
June 13, 1996
<PAGE>
EXHIBIT 23.3
INDEPENDENT AUDITORS' CONSENT
We consent to the incorporation by reference in Amendment No. 2 to Registration
Statement No. 33-80571, Post-Effective Amendment No. 7 to Registration Statement
No. 33-44329, and Post-Effective Amendment No. 3 to Statement No. 33-86920 of
SMT Health Services, Inc. of our report dated March 4, 1994, on the financial
statements of SMT Health Services, Inc. for the year ended December 31, 1993,
appearing in Form 10-K/A (Amendment No. 1) of SMT Health Services, Inc. for the
year ended December 31, 1995, and to the reference to us under the headings
"Experts" in the Prospectuses, which are a part of the Registration Statements.
Deloitte & Touche LLP
Pittsburgh, Pennsylvania
June 14, 1996
